var title_f38_36_39488="Phenylephrine: Drug information";
var content_f38_36_39488=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Phenylephrine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12618183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/7/19572?source=see_link\">",
"       Phenylephrine (nasal): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/7/23668?source=see_link\">",
"       Phenylephrine (ophthalmic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/47/6903?source=see_link\">",
"       Phenylephrine (systemic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/53/30547?source=see_link\">",
"       Phenylephrine (topical): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9768 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-8D972B75FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_36_39488=[""].join("\n");
var outline_f38_36_39488=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?19/7/19572?source=related_link\">",
"      Phenylephrine (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/7/23668?source=related_link\">",
"      Phenylephrine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?6/47/6903?source=related_link\">",
"      Phenylephrine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/53/30547?source=related_link\">",
"      Phenylephrine (topical): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_36_39489="Blunt chest trauma in adults algorithm";
var content_f38_36_39489=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F81674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F81674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 614px\">",
"   <div class=\"ttl\">",
"    Blunt chest trauma in adults ED management algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 606px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AP: anterior-posterior; CT: computed tomography; CXR: chest x-ray; ECG: electrocardiogram; ED: emergency department; FAST: Focused Assessment with Sonography in Trauma; OR: operating room; PA: posterior-anterior; PTX: pneumothorax; TEE: transesophageal echocardiography; US: ultrasound.",
"     <br/>",
"     * This algorithm is a general guide; sophisticated imaging may not be necessary in all circumstances.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_36_39489=[""].join("\n");
var outline_f38_36_39489=null;
var title_f38_36_39490="Superfical temporal artery";
var content_f38_36_39490=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F82876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F82876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superfical temporal artery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 579px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_36_39490=[""].join("\n");
var outline_f38_36_39490=null;
var title_f38_36_39491="Bell clapper deformity";
var content_f38_36_39491=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bell clapper deformity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 404px; height: 493px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the \"bell clapper\" deformity, the testis lies horizontally and the tunica vaginalis extends up over the spermatic cord so that the testis is suspended within the tunica vaginalis by the spermatic cord.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_36_39491=[""].join("\n");
var outline_f38_36_39491=null;
var title_f38_36_39492="Acetaminophen and diphenhydramine: Patient drug information";
var content_f38_36_39492=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"20\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Acetaminophen and diphenhydramine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33030?source=see_link\">",
"     see \"Acetaminophen and diphenhydramine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F129540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aceta-Gesic&reg;;",
"     </li>",
"     <li>",
"      Excedrin PM&reg; [OTC];",
"     </li>",
"     <li>",
"      Goody's PM&reg; [OTC];",
"     </li>",
"     <li>",
"      Legatrin PM&reg; [OTC];",
"     </li>",
"     <li>",
"      Mapap PM [OTC];",
"     </li>",
"     <li>",
"      Percogesic&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      TopCare&reg; Pain Relief PM [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; PM [OTC];",
"     </li>",
"     <li>",
"      Tylenol&reg; Severe Allergy [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692082",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat sleep problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to acetaminophen, diphenhydramine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696680",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid other sources of acetaminophen. An overdose may cause problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man with problems passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid or limit drinking wine, beer, or mixed drinks to less than 3 drinks a day. Drinking too much alcohol may raise your chance of liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694768",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take more than what your doctor told you to take. Liver problems may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695837",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 30 to 60 minutes before bedtime if using for sleep. Do not take for more than 2 weeks in a row.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694218",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695424",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix the powder with liquid and drink or place on your tongue and swallow with liquid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12517 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-201.211.0.116-1BDAF23249-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_36_39492=[""].join("\n");
var outline_f38_36_39492=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129540\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026542\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026541\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026546\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026547\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026549\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026544\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026545\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026550\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026551\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?32/16/33030?source=related_link\">",
"      Acetaminophen and diphenhydramine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_36_39493="How to dilate cervix";
var content_f38_36_39493=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77607&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 557px\">",
"   <div class=\"ttl\">",
"    Cervical dilation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 537px; height: 414px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_36_39493=[""].join("\n");
var outline_f38_36_39493=null;
var title_f38_36_39494="Hamartin tuberin complex";
var content_f38_36_39494=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F58634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F58634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Hamartin-tuberin complex: Central regulator of cell-signalling",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 743px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After growth-factor stimulation, the hamartin-tuberin complex is phosphorylated and its GTPase-activating protein activity is decreased, whereas in response to stimuli such as hypoxia or low energy it is phosphorylated and its GTPase-activating protein activity increased. The complex deactivates RHEB by causing GTP to be cleaved from it. Activated RHEB stimulates mTOR, which has a crucial role in the translation of proteins such as c-Myc or ornithine decarboxylase, and participates in cell-cycle control. mTOR binds to raptor and G&beta;L to exert its effect, which is mediated by S6K1 and 4E-BP1, proteins that participate in ribosome biogenesis and translation initiation, respectively. Nutrients might boost translation through PI3KIII, which phosphorylates mTOR. TSC1 and TSC2 interact also with other proteins, such as ER&alpha;, calmodulin, p27, SMAD2, 14-3-3 proteins, and PAM.",
"    <div class=\"footnotes\">",
"     4E-BP1: eukaryotic translation initiation factor 4E binding protein 1; AKT: protein kinase B; AMPK: AMP-activated protein kinase; CDK1: cyclin-dependent kinase 1; ERK: extracellular signal-regulated protein kinase; G&beta;L: G protein &beta;-subunit like; GSK3&beta;: glycogen synthase kinase 3&beta;; PAM: protein associated with Myc; PI3KIII: PtdIns 3-kinase; REDD1: regulated in development and DNA damage responses; RHEB: Ras homologue enriched in brain; RSK1: ribosomal S6 kinase 1; S6K1: kinase that activates ribosomal subunit S6.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet 2008; 372:657. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_36_39494=[""].join("\n");
var outline_f38_36_39494=null;
var title_f38_36_39495="Diagnosis of polycystic ovary syndrome in adults";
var content_f38_36_39495=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis of polycystic ovary syndrome in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/36/39495/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/36/39495/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/36/39495/contributors\">",
"     David A Ehrmann, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/36/39495/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/36/39495/contributors\">",
"     William F Crowley, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/36/39495/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/36/39495/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/36/39495/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The polycystic ovary syndrome (PCOS) is an important cause of both menstrual irregularity and androgen excess in women. When fully expressed (hirsutism, irregular menstrual cycles, obesity, and a classic ovarian morphology), PCOS can be readily diagnosed. However, there has been considerable controversy about specific diagnostic criteria when not all of these classic features are evident [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39495/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of PCOS will be reviewed here. The epidemiology and pathogenesis, clinical manifestations, and treatment of PCOS are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40568?source=see_link\">",
"     \"Epidemiology and pathogenesis of the polycystic ovary syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/6/16490?source=see_link\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/49/1817?source=see_link\">",
"     \"Treatment of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC CRITERIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several professional groups have proposed diagnostic criteria for PCOS, using the criteria of ovulatory dysfunction, hyperandrogenism, polycystic ovaries, and exclusion of other disorders in varying combinations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     NIH consensus criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;After considerable debate at a 1990 National Institutes of Health Conference on PCOS, minimal criteria for diagnosing PCOS were proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39495/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Menstrual irregularity due to oligo- or anovulation",
"     </li>",
"     <li>",
"      Evidence of hyperandrogenism, whether clinical (hirsutism, acne, or male pattern balding)",
"      <strong>",
"       or",
"      </strong>",
"      biochemical (high serum androgen concentrations)",
"     </li>",
"     <li>",
"      Exclusion of other causes of hyperandrogenism and menstrual irregularity, such as congenital adrenal hyperplasia, androgen-secreting tumors, and hyperprolactinemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Rotterdam criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Revised diagnostic criteria have been proposed based upon a 2003 consensus meeting held in Rotterdam (European Society of Human Reproduction and",
"    <span class=\"nowrap\">",
"     Embryology/American",
"    </span>",
"    Society of Reproductive Medicine consensus workshop group) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39495/abstract/3\">",
"     3",
"    </a>",
"    ]. These criteria encompass a broader spectrum of phenotypes considered to represent PCOS. In the revised criteria, two out of three of the following are required to make the diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Oligo-",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anovulation",
"     </li>",
"     <li>",
"      Clinical",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      biochemical signs of hyperandrogenism",
"     </li>",
"     <li>",
"      Polycystic ovaries (by ultrasound)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, other etiologies (congenital adrenal hyperplasias, androgen-secreting tumors, Cushing's syndrome) must be excluded.",
"   </p>",
"   <p>",
"    The ultrasound criteria for polycystic ovaries (PCO) have evolved since the first description in 1986. The current criteria (used for the Rotterdam criteria), considered to have sufficient specificity and sensitivity to define PCO, are the presence of 12 or more follicles in each ovary measuring 2 to 9 mm in diameter",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased ovarian volume (&gt;10 mL; calculated using the formula 0.5 x length x width x thickness). One ovary fitting this definition is sufficient to define PCOS. It was suggested that follicle distribution and an increase in stromal echogenicity and volume be eliminated as diagnostic criteria.",
"   </p>",
"   <p>",
"    The transvaginal approach should be used. Women with the ultrasound appearance of PCO in the absence of",
"    <span class=\"nowrap\">",
"     oligo/amenorrhea",
"    </span>",
"    or hyperandrogenism should",
"    <strong>",
"     not",
"    </strong>",
"    be considered to have PCOS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     AES criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the continuing controversy regarding the definition of PCOS, the Androgen Excess Society (AES) proposed that PCOS should be diagnosed by the presence of three features: androgen excess (clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biochemical hyperandrogenism), ovarian dysfunction (oligo-anovulation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    polycystic ovarian morphology), and exclusion of other androgen excess or ovulatory disorders (",
"    <a class=\"graphic graphic_table graphicRef65205 \" href=\"mobipreview.htm?25/33/26139\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39495/abstract/4\">",
"     4",
"    </a>",
"    ]. This definition then recognizes one additional phenotype above that noted by the NIH 1990 criteria, namely that of women with polycystic ovaries, hyperandrogenism, and apparently normal ovulation. In contrast to the Rotterdam criteria, the AES task force agreed that there were insufficient data to define women with ovulatory dysfunction and polycystic ovaries (but without any evidence of hyperandrogenism) as having PCOS.",
"   </p>",
"   <p>",
"    The NIH criteria allow for a clinical diagnosis without the use of an imaging study. In addition, the NIH criteria require the presence of irregular menses, while the other criteria do not. Therefore, the Rotterdam and AES criteria encompass a broader spectrum of phenotypes considered to represent PCOS.",
"   </p>",
"   <p>",
"    We continue to use the NIH criteria to make the diagnosis of PCOS. The current Rotterdam ultrasound criteria for the diagnosis of polycystic ovaries are precise, but often loosely applied. From a practical perspective, unless one is working with an experienced ultrasonographer, these criteria may be difficult to document.",
"   </p>",
"   <p>",
"    There is emerging evidence that serum concentrations of anti-M&uuml;llerian hormone (AMH) may be useful in the diagnosis of PCOS. In one study, serum concentrations of AMH were two- to threefold higher in women with PCOS compared with normal ovulatory women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39495/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, the number of small antral follicles detected on transvaginal imaging appears to be correlated with serum AMH concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39495/abstract/6\">",
"     6",
"    </a>",
"    ]. However, an elevated AMH is not currently considered to be a criterion for the diagnosis of PCOS.",
"   </p>",
"   <p>",
"    The diagnosis of PCOS in adolescents is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/13/39130?source=see_link\">",
"     \"Clinical features and diagnosis of polycystic ovary syndrome in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Menstrual irregularity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The menstrual irregularity typically begins in the peripubertal period, and menarche may be delayed. The menstrual pattern may be one of oligomenorrhea (fewer than nine menstrual periods in a year) or amenorrhea (no menstrual periods for three or more consecutive months). In addition to menstrual irregularity, cycles are usually anovulatory, resulting in heavy bleeding at times, and an increased risk of endometrial hyperplasia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/6/16490?source=see_link\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Biochemical evaluation of the oligomenorrhea is the same as in women with these disorders in the absence of PCOS. In addition to measurement of serum hCG to rule out pregnancy, minimal laboratory testing should include measurements of serum prolactin, thyrotropin, and FSH to rule out hyperprolactinemia, thyroid disease, and ovarian failure (high serum FSH in primary ovarian disease), respectively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34697?source=see_link&amp;anchor=H16#H16\">",
"     \"Etiology, diagnosis, and treatment of secondary amenorrhea\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hyperandrogenism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most women with PCOS have both clinical and biochemical evidence of hyperandrogenism, but only one or the other is required to make the diagnosis. The major clinical manifestations of hyperandrogenism are hirsutism, acne, and male-pattern hair loss. Signs of more severe androgen excess (virilization), such as deepening of the voice and clitoromegaly, occur only rarely, so these signs should prompt the search for androgen-producing neoplasms.",
"   </p>",
"   <p>",
"    Hirsutism is defined as excess terminal (thick pigmented) body hair in a male distribution, and is commonly noted on the upper lip, chin, periareolarly, in the midsternum, and along the linea alba of the lower abdomen (",
"    <a class=\"graphic graphic_picture graphicRef73544 \" href=\"mobipreview.htm?5/5/5203\">",
"     picture 1",
"    </a>",
"    ). There is substantial ethnic variability in hirsutism; Asian women, as an example, often have a lesser degree of hirsutism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39495/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/28/24007?source=see_link\">",
"     \"Pathogenesis and causes of hirsutism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Serum androgens",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do not routinely measure serum androgen concentrations in women with mild hirsutism. However, in women with moderate to severe hirsutism, we typically measure a total and free testosterone concentration, and if there are concerns about a possible androgen-secreting tumor causing the hyperandrogenism, we add serum dehydroepiandrosterone sulfate (DHEA-S). Other tests that should be considered depend upon the clinical presentation and are described below. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Differential diagnosis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H19\">",
"     'Androgen-secreting tumors'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34697?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of secondary amenorrhea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/31/9721?source=see_link\">",
"     \"Evaluation of premenopausal women with hirsutism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Depending upon which androgens are measured, 50 to 90 percent of PCOS women will have an elevated serum androgen concentration (",
"    <a class=\"graphic graphic_figure graphicRef72842 \" href=\"mobipreview.htm?21/25/21918\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39495/abstract/8\">",
"     8",
"    </a>",
"    ]. The excess androgens can be derived from the ovary, the adrenal cortex, or both (",
"    <a class=\"graphic graphic_table graphicRef60049 \" href=\"mobipreview.htm?19/41/20123\">",
"     table 2",
"    </a>",
"    ). In one report of 716 women with PCOS diagnosed by the presence of both oligoovulation and clinical hyperandrogenism (National Institutes of Health 1990 criteria), the overall prevalence of hyperandrogenemia was 75 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39495/abstract/9\">",
"     9",
"    </a>",
"    ]. Supranormal levels of free testosterone (&gt;0.76",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    [.026",
"    <span class=\"nowrap\">",
"     nmol/L]),",
"    </span>",
"    total testosterone (&gt;88",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    [3.05",
"    <span class=\"nowrap\">",
"     nmol/L]),",
"    </span>",
"    and DHEA-S (&gt;2.75",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [7463",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    were seen in 58, 33, and 33 percent of women, respectively.",
"   </p>",
"   <p>",
"    An elevation in free testosterone is the most sensitive test to establish the presence of hyperandrogenemia. This is because elevated insulin levels (a frequent concomitant of PCOS) and elevated androgen levels both act to inhibit hepatic production of sex hormone-binding globulin (SHBG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39495/abstract/10\">",
"     10",
"    </a>",
"    ]. However, commercially available free testosterone assays are often unreliable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12824?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical features and diagnosis of male hypogonadism\", section on 'Laboratory tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other biochemical findings that are often, but not universally present, may include elevation of serum luteinizing hormone (LH) concentrations, normal serum estradiol, and increased serum estrone concentrations. None of these hormones are part of the diagnostic criteria for PCOS and, therefore, do not need to be measured.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pelvic ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of PCOS using the NIH consensus criteria does not require the presence of polycystic ovaries, as detected by ultrasonography (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55767 \" href=\"mobipreview.htm?42/40/43649\">",
"     image 1",
"    </a>",
"    ), although 80 to 100 percent of women with the PCOS do have polycystic ovaries on ultrasound, defined using the original 1986 criteria as the presence of eight or more small (2 to 8 mm) follicles in each ovary. However, the polycystic appearance is non-specific, since it can also be seen in women with idiopathic hirsutism, other androgen excess disorders, and even normal women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39495/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/6/16490?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\", section on 'Ultrasound appearance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Rotterdam criteria include polycystic ovaries on ultrasound as one of the diagnostic criteria. Their revised ultrasound criteria for polycystic ovaries are described above. From a practical perspective, unless one is working with an experienced ultrasonographer, these criteria may be difficult to document. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Rotterdam criteria'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Of note, ovarian volume and follicle number decrease with age in women with PCOS. Age-based criteria to define polycystic ovarian morphology have therefore been proposed to identify PCOS in women over age 40 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39495/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62513584\">",
"    <span class=\"h2\">",
"     Mood disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence that PCOS is associated with mood disorders (depression and anxiety), impaired quality of life, and eating disorders (binge eating), even when compared to women with the same BMI. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/6/16490?source=see_link&amp;anchor=H62513921#H62513921\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\", section on 'Mood disorders'",
"    </a>",
"    .) Based upon these observations, The Androgen Excess and PCOS Society suggests screening all women with PCOS for mood disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39495/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, women should be asked about their quality of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Metabolic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;An overview of the metabolic abnormalities, including the metabolic syndrome, in women with PCOS is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/6/16490?source=see_link\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Dyslipidemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipid abnormalities, in particular low serum HDL, high serum triglycerides, and high serum LDL concentrations are common in women with PCOS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/6/16490?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\", section on 'Dyslipidemia'",
"    </a>",
"    .) We suggest a fasting lipid profile in women with newly diagnosed PCOS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     OGTT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both lean and obese women with PCOS may have insulin resistance and hyperinsulinemia. In addition, many obese women with PCOS are diagnosed with impaired glucose tolerance (up to 35 percent) or type 2 diabetes mellitus (up to 10 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39495/abstract/15\">",
"     15",
"    </a>",
"    ]. A standard fasting glucose measurement lacks the sensitivity to detect impaired glucose tolerance or early type 2 diabetes that will be present on an OGTT in a substantial number of women, as noted above. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/6/16490?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\", section on 'Type 2 diabetes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/54/38758?source=see_link\">",
"     \"Diagnosis of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of professional organizations, including the American College of Obstetricians and Gynecologists (ACOG), American Association of Clinical Endocrinologists (AACE) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39495/abstract/16\">",
"     16",
"    </a>",
"    ], the Androgen Excess Society [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39495/abstract/17\">",
"     17",
"    </a>",
"    ], and a consensus panel representing the European Society of Human Reproduction and Embryology (ESHRE) and the American Society of Reproductive Medicine (ASRM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39495/abstract/3\">",
"     3",
"    </a>",
"    ] recommend a baseline two-hour OGTT (with measurement of fasting and two-hour glucose) in all women with PCOS.",
"   </p>",
"   <p>",
"    The Androgen Excess Society also suggests the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39495/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with normal glucose tolerance should be rescreened at least once every two years or more frequently if additional risk factors are identified.",
"     </li>",
"     <li>",
"      Patients with impaired glucose tolerance should be screened annually for development of type 2 diabetes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We agree with these recommendations and suggest performing a two-hour OGTT in women with PCOS. If this is not feasible, a fasting glucose should be obtained together with a measurement of the hemoglobin A1C concentration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/54/38758?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnosis of diabetes mellitus\", section on 'ADA criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although endocrinologists suggest performing an OGTT, many internists and family practice specialists prefer screening with a fasting glucose alone. The shortcoming of this strategy, however, is that it does not allow for the identification of those subjects with impaired glucose tolerance who are at highest risk for the subsequent conversion to type 2 diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Insulin resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;There currently is no validated test for measuring insulin resistance in a clinical setting. The hyperinsulinemic-euglycemic clamp and the frequently sampled intravenous glucose tolerance test are research procedures. While calculated indices using fasting insulin and glucose concentrations are sometimes used (eg, glucose to insulin ratios, homeostasis model assessment of insulin resistance [HOMA-IR or HOMA]), there are limitations to their use, including changes in beta-cell function over time, lack of a standardized universal insulin assay, and lack of data demonstrating that markers of insulin resistance predict response to treatment. As a result, we do not recommend routine assessment of insulin resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Metabolic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Rotterdam consensus meeting described above suggested the following approach to screening for metabolic disorders in women with PCOS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39495/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No tests of insulin resistance are necessary to make the diagnosis of PCOS, nor are they needed to select treatments.",
"     </li>",
"     <li>",
"      Obese women with PCOS should be screened for the metabolic syndrome (by measuring waist circumference, blood pressure, fasting lipids, and a fasting and two-hour glucose from an OGTT). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'OGTT'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=see_link\">",
"       \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      They suggest a similar approach in non-obese women with PCOS if there are risk factors such as a family history of type 2 diabetes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A similar approach to metabolic testing is described in a 2010 Consensus statement from the Androgen Excess and Polycystic Ovary Syndrome Society [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39495/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of PCOS is viewed by some as one of exclusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39495/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Other causes of hyperandrogenism include hyperprolactinemia, drugs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/0/26629?source=see_link\">",
"     danazol",
"    </a>",
"    and androgenic progestins), nonclassic congenital adrenal hyperplasia, ovarian and adrenal tumors, and Cushing's syndrome (",
"    <a class=\"graphic graphic_table graphicRef65205 \" href=\"mobipreview.htm?25/33/26139\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/28/24007?source=see_link\">",
"     \"Pathogenesis and causes of hirsutism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The main diagnostic question is how best to identify the small number of women who have other causes for the clinical constellation of findings similar to those seen in PCOS. Several clinical findings suggest one of the rare causes of hirsutism:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abrupt onset, short duration (typically less than one year), or sudden progressive worsening of hirsutism.",
"     </li>",
"     <li>",
"      Onset of clinical symptoms in the third decade of life or later, rather than near puberty.",
"     </li>",
"     <li>",
"      Symptoms or signs of virilization, including frontal balding, severe pustular acne, clitoromegaly, increased muscle mass, or deepening of voice.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The less common causes of hirsutism can usually be distinguished from PCOS by a few additional clinical features and few biochemical tests. As examples:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Nonclassic CAH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonclassic congenital adrenal hyperplasia (CAH; due to 21-hydroxylase deficiency) is less common than PCOS, and can be ruled out by measurement of serum 17-hydroxyprogesterone. This test can be limited to high-risk groups (eg, women of Eastern European Jewish [Ashkenazi] heritage who have a 1:27 prevalence) because of the rarity of the disorder in the general female population. Other groups to consider testing are women of Hispanic, Slavic, or Italian descent, in whom the prevalence is 1:40, 1:50, and 1:300 women, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39495/abstract/21\">",
"     21",
"    </a>",
"    ]. When hirsutism alone is the issue, some endocrinologists do not pursue this diagnosis given that antiandrogen therapy can be as effective as glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39495/abstract/22\">",
"     22",
"    </a>",
"    ]. Women with nonclassic congenital adrenal hyperplasia do not have adrenal insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/6/19560?source=see_link\">",
"     \"Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A morning serum 17-hydroxyprogesterone concentration greater than 200",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (6",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    in the early follicular phase strongly suggests the diagnosis, which may be confirmed by a high dose (250 mcg)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/20/24902?source=see_link\">",
"     ACTH stimulation test",
"    </a>",
"    . The diagnosis is excluded by a post-ACTH serum 17-hydroxyprogesterone value less than 1000",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (30",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39495/abstract/23\">",
"     23",
"    </a>",
"    ]. Most patients have values exceeding 1500",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (43",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    after ACTH stimulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Androgen-secreting tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with androgen-secreting ovarian or adrenal tumors usually have progressive hirsutism, some signs of virilization, and amenorrhea. Their serum testosterone concentrations are nearly always higher than 150",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (5.2",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39495/abstract/24\">",
"     24",
"    </a>",
"    ], and those with adrenal tumors usually have serum dehydroepiandrosterone sulfate concentrations higher than 800",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (21.6",
"    <span class=\"nowrap\">",
"     &micro;mol/L).",
"    </span>",
"    Their serum LH concentrations are low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H103456320\">",
"    <span class=\"h2\">",
"     Hyperprolactinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most women with hyperprolactinemia have prominent menstrual dysfunction but little hyperandrogenism; high serum prolactin concentrations establish the diagnosis. Some hyperandrogenic women have mildly elevated serum prolactin levels of uncertain significance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19254?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hyperprolactinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/6/16490?source=see_link\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/29/28115?source=see_link\">",
"       \"Patient information: Polycystic ovary syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/46/30437?source=see_link\">",
"       \"Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;We continue to use the NIH criteria to make the diagnosis of PCOS, which requires the presence of oligomenorrhea, evidence of hyperandrogenism, and exclusion of other causes of hyperandrogenism and menstrual irregularity. The hyperandrogenism may be diagnosed by either clinical (acne, hirsutism, or male-pattern hair loss) or biochemical (elevated serum androgen concentration) criteria. Therefore, a patient with oligomenorrhea and clinical evidence of hyperandrogenism but normal serum androgen concentrations is still considered to have PCOS.",
"   </p>",
"   <p>",
"    In the Rotterdam criteria, two out of three of the following are required to make the diagnosis: oligomenorrhea, hyperandrogenism, and polycystic ovaries on ultrasound. However, the current Rotterdam ultrasound criteria for the diagnosis of polycystic ovaries are precise, but often loosely applied. From a practical perspective, unless one is working with an experienced ultrasonographer, these criteria may be difficult to document. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'NIH consensus criteria'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4\">",
"     'Rotterdam criteria'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Biochemical tests",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In women with oligomenorrhea, in addition to measurement of serum hCG to rule out pregnancy, minimal laboratory testing should include measurements of serum prolactin, thyrotropin, and FSH to rule out hyperprolactinemia, thyroid disease, and ovarian failure, respectively. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34697?source=see_link&amp;anchor=H16#H16\">",
"       \"Etiology, diagnosis, and treatment of secondary amenorrhea\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We do not routinely measure serum androgen concentrations in women with mild hirsutism. However, in women with moderate to severe hirsutism, we typically measure a total and free testosterone concentration, and if there are concerns about a possible androgen-secreting tumor causing the hyperandrogenism, we add serum dehydroepiandrosterone sulfate (DHEA-S). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34697?source=see_link\">",
"       \"Etiology, diagnosis, and treatment of secondary amenorrhea\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/31/9721?source=see_link\">",
"       \"Evaluation of premenopausal women with hirsutism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Approximately 45 percent of women with PCOS have IGT or type 2 diabetes. A fasting glucose measurement is a less sensitive test than oral glucose tolerance testing for diagnosing IGT and diabetes in women with PCOS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/6/16490?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\", section on 'Type 2 diabetes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once the diagnosis of PCOS is made, we perform an OGTT in all patients. When this is not practical, a fasting glucose along with a hemoglobin A1C can be obtained. If either one is abnormal, an OGTT should be performed to distinguish between IGT and diabetes.",
"     </li>",
"     <li>",
"      Given the high prevalence of lipid abnormalities in PCOS, we suggest measuring a fasting lipid profile in all women with the disorder.",
"     </li>",
"     <li>",
"      Consideration should be given to obtaining an overnight polysomnogram to exclude obstructive sleep apnea.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39495/abstract/1\">",
"      Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352:1223.",
"     </a>",
"    </li>",
"    <li>",
"     Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. In: Polycystic Ovary Syndrome (Current Issues in Endocrinology and Metabolism), Dunaif A, Givens JR, Haseltine FP, Merriam GE (Eds), Blackwell Scientific Inc., Boston 1992. p.377.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39495/abstract/3\">",
"      Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39495/abstract/4\">",
"      Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009; 91:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39495/abstract/5\">",
"      Laven JS, Mulders AG, Visser JA, et al. Anti-M&uuml;llerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004; 89:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39495/abstract/6\">",
"      Pigny P, Jonard S, Robert Y, Dewailly D. Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 91:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39495/abstract/7\">",
"      Carmina E, Koyama T, Chang L, et al. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am J Obstet Gynecol 1992; 167:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39495/abstract/8\">",
"      DeVane GW, Czekala NM, Judd HL, Yen SS. Circulating gonadotropins, estrogens, and androgens in polycystic ovarian disease. Am J Obstet Gynecol 1975; 121:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39495/abstract/9\">",
"      Huang A, Brennan K, Azziz R. Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria. Fertil Steril 2010; 93:1938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39495/abstract/10\">",
"      Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996; 335:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39495/abstract/11\">",
"      Polson DW, Adams J, Wadsworth J, Franks S. Polycystic ovaries--a common finding in normal women. Lancet 1988; 1:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39495/abstract/12\">",
"      Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed) 1986; 293:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39495/abstract/13\">",
"      Alsamarai S, Adams JM, Murphy MK, et al. Criteria for polycystic ovarian morphology in polycystic ovary syndrome as a function of age. J Clin Endocrinol Metab 2009; 94:4961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39495/abstract/14\">",
"      Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010; 95:2038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39495/abstract/15\">",
"      Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39495/abstract/16\">",
"      American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Committee. American Association of Clinical Endocrinologists Position Statement on Metabolic and Cardiovascular Consequences of Polycystic Ovary Syndrome. Endocr Pract 2005; 11:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39495/abstract/17\">",
"      Salley KE, Wickham EP, Cheang KI, et al. Glucose intolerance in polycystic ovary syndrome--a position statement of the Androgen Excess Society. J Clin Endocrinol Metab 2007; 92:4546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39495/abstract/18\">",
"      Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981; 140:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39495/abstract/19\">",
"      Barbieri RL. Hyperandrogenic disorders. Clin Obstet Gynecol 1990; 33:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39495/abstract/20\">",
"      O'Driscoll JB, Mamtora H, Higginson J, et al. A prospective study of the prevalence of clear-cut endocrine disorders and polycystic ovaries in 350 patients presenting with hirsutism or androgenic alopecia. Clin Endocrinol (Oxf) 1994; 41:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39495/abstract/21\">",
"      New MI. Nonclassic 21-hydroxylase deficiency. Fertil Steril 2006; 86 Suppl 1:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39495/abstract/22\">",
"      Spritzer P, Billaud L, Thalabard JC, et al. Cyproterone acetate versus hydrocortisone treatment in late-onset adrenal hyperplasia. J Clin Endocrinol Metab 1990; 70:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39495/abstract/23\">",
"      Azziz R, Dewailly D, Owerbach D. Clinical review 56: Nonclassic adrenal hyperplasia: current concepts. J Clin Endocrinol Metab 1994; 78:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39495/abstract/24\">",
"      Derksen J, Nagesser SK, Meinders AE, et al. Identification of virilizing adrenal tumors in hirsute women. N Engl J Med 1994; 331:968.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7385 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-458F631DC3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_36_39495=[""].join("\n");
var outline_f38_36_39495=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSTIC CRITERIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NIH consensus criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Rotterdam criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      AES criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Menstrual irregularity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hyperandrogenism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Serum androgens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pelvic ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H62513584\">",
"      Mood disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Metabolic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - OGTT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Insulin resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Metabolic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Nonclassic CAH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Androgen-secreting tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H103456320\">",
"      Hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Biochemical tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7385\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7385|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?42/40/43649\" title=\"diagnostic image 1\">",
"      Polycystic ovary ultrasound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7385|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/25/21918\" title=\"figure 1\">",
"      Androgen levels in PCOS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7385|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/5/5203\" title=\"picture 1\">",
"      Hirsutism in PCOS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7385|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/33/26139\" title=\"table 1\">",
"      Causes of hirsutism in women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/41/20123\" title=\"table 2\">",
"      Androgens in PCOS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12824?source=related_link\">",
"      Clinical features and diagnosis of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/13/39130?source=related_link\">",
"      Clinical features and diagnosis of polycystic ovary syndrome in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19254?source=related_link\">",
"      Clinical manifestations and diagnosis of hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/6/16490?source=related_link\">",
"      Clinical manifestations of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/54/38758?source=related_link\">",
"      Diagnosis of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40568?source=related_link\">",
"      Epidemiology and pathogenesis of the polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34697?source=related_link\">",
"      Etiology, diagnosis, and treatment of secondary amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/31/9721?source=related_link\">",
"      Evaluation of premenopausal women with hirsutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/6/19560?source=related_link\">",
"      Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/28/24007?source=related_link\">",
"      Pathogenesis and causes of hirsutism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?29/46/30437?source=related_link\">",
"      Patient information: Polycystic ovary syndrome (PCOS) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/29/28115?source=related_link\">",
"      Patient information: Polycystic ovary syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/49/1817?source=related_link\">",
"      Treatment of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_36_39496="Population stratification";
var content_f38_36_39496=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 599px\">",
"   <div class=\"ttl\">",
"    Population stratification",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 579px; height: 536px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_36_39496=[""].join("\n");
var outline_f38_36_39496=null;
var title_f38_36_39497="Amsler grid";
var content_f38_36_39497=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F56604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F56604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 511px\">",
"   <div class=\"ttl\">",
"    Examples of two different Amsler grids",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 491px; height: 521px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Both are useful for monitoring central vision.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Vitreous Retina Macula Consultants of New York. file://www.vrmny.com/amsler.htm.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_36_39497=[""].join("\n");
var outline_f38_36_39497=null;
var title_f38_36_39498="Management of stage III non-small cell lung cancer";
var content_f38_36_39498=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of stage III non-small cell lung cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/36/39498/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/36/39498/contributors\">",
"     Steven E Schild, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/36/39498/contributors\">",
"     Suresh S Ramalingam, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/36/39498/contributors\">",
"     Eric Valli&egrave;res, MD, FRCSC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/36/39498/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/36/39498/contributors\">",
"     Rogerio C Lilenbaum, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/36/39498/contributors\">",
"     Brian Kavanagh, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/36/39498/contributors\">",
"     Joseph S Friedberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/36/39498/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/36/39498/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/36/39498/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Development of a therapeutic plan for a patient with lung cancer depends upon the cell type (small cell versus non-small cell), tumor stage, and an assessment of the patient's overall medical condition. Non-small cell lung cancer (NSCLC) includes adenocarcinoma and its bronchioloalveolar subset, squamous cell carcinoma, and large cell carcinoma, in decreasing order frequency of occurrence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/43/22201?source=see_link\">",
"     \"Pathology of lung malignancies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of patients with stage III NSCLC, which usually requires a combined modality approach, will be reviewed here. The approach to staging of NSCLC and its implications for prognosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/31/14841?source=see_link\">",
"     \"Diagnosis and staging of non-small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/21/44373?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system for non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109591591\">",
"    <span class=\"h2\">",
"     TNM staging system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tumor (T), node (N), metastasis (M) system is used to stage NSCLC (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"mobipreview.htm?36/41/37533\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef68104 \" href=\"mobipreview.htm?13/4/13388\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/1\">",
"     1",
"    </a>",
"    ]. Historically stage III lung cancer was defined as locoregionally advanced disease due to primary tumor extension into extrapulmonary structures (T3 or T4) or mediastinal lymph node involvement (N2 or N3) without evidence of distant metastases (M0). With the 2009 revisions to the TNM staging system, stage III lung cancers now include T3 tumors greater than 7 cm in size and T3 tumors with multiple nodules in the same lobe, when associated with N1 involvement. Noncontiguous pleural involvement by tumor is classified as stage IV in the current TNM system (formerly stage III). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/21/44373?source=see_link&amp;anchor=H4#H4\">",
"     \"Tumor node metastasis (TNM) staging system for non-small cell lung cancer\", section on 'Seventh edition of the TNM system'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with stage IIIA disease are stratified clinically into those with bulky or nonbulky mediastinal lymph node disease. The definition of bulky mediastinal lymphadenopathy varies in the literature, but a reasonable definition is lymph nodes greater than 2 to 3 cm in short-axis diameter, as measured by CT, groupings of multiple smaller lymph nodes, or involvement of more than two lymph node stations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The distinction between nonbulky and bulky stage IIIA and IIIB disease is primarily useful in selecting appropriate patients for surgical resection after neoadjuvant therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109591606\">",
"    <span class=\"h2\">",
"     Mediastinal evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important component of the staging evaluation is an assessment of the mediastinal lymph nodes. Absence of tumor involvement of the mediastinal lymph nodes remains one of the most important factors in selecting treatment for patients with potentially resectable NSCLC.",
"   </p>",
"   <p>",
"    Patients with either enlarged mediastinal lymph nodes by CT criteria or metabolically active lymph nodes by PET criteria should undergo cytologic or pathologic evaluation of the mediastinal lymph nodes. If lymph nodes are pathologically involved by tumor, then the patient has at least stage III disease and a combined modality therapy approach is most appropriate. If mediastinal lymph nodes are negative by pathologic evaluation, then the patient has clinical stage I or II disease and resection of the primary tumor along with further mediastinal lymph node sampling is in order. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/5/1114?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of stage I and stage II non-small cell lung cancer\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients without suggestion of N1 or N2-3 lymph node involvement by both CT and PET criteria, the role of cytologic or pathologic evaluation of the mediastinal lymph nodes is more involved:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Invasive mediastinal staging is indicated for all patients with central tumors, those with potentially resectable T2, T3, and T4 tumors, and those with tumors with enlarged hilar lymph nodes by CT",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      clinical N1 involvement by PET, even if the mediastinum appears clean by both CT and PET criteria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The role of preoperative pathologic evaluation of mediastinal lymph nodes for patients with a peripheral T1a primary lesion and no suggestion of N1 or N2-3 lymph node involvement by both CT and PET criteria is controversial:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Some centers will proceed directly to primary resection without preoperative pathologic evaluation of mediastinal lymph nodes in view of the low incidence of involved mediastinal nodes identified at mediastinoscopy in this selected population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, other centers advocate offering mediastinoscopy, because of the impact on management strategy when occult lymph node metastases are detected. As an example, in one study 6.5 percent of patients with T1 primary lesions had occult N2 disease despite a negative CT and PET of the mediastinum [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the past, the distinction between ipsilateral (N2) versus contralateral (N3) lymphadenopathy was primarily used to select patients for an operative versus non-operative approach. In general, patients with bulky stage IIIA or stage IIIB disease were considered inoperable, while those with nonbulky stage IIIA NSCLC were considered potentially resectable for cure. However, the recognition that surgery alone rarely cured patients with even nonbulky stage IIIA NSCLC led to a shift away from upfront surgery in favor of combined modality approaches. Treatment of patients with N3 disease remains nonsurgical outside of a clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment of patients with stage III NSCLC has not been clearly defined and many aspects of therapy remain controversial. While there are many potential treatment options, none yields a high probability of cure.",
"   </p>",
"   <p>",
"    Due to the heterogeneity that is inherent in stage III disease, no single approach can be recommended for all patients. In addition to the location of the primary tumor and the extent of involvement of the mediastinal lymph nodes, other patient factors, such as pulmonary function and overall performance status, must be considered in developing an individualized treatment plan. Although most patients with stage III NSCLC will die from the disease, the overall goal of treatment is cure. However, the extent of disease or poor performance status may preclude curative approaches for some patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Limitations of clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data supporting specific therapeutic approaches for stage III disease are derived from trials that are subject to a number of significant limitations. These fall into several categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Heterogeneous patient populations &mdash; Many clinical trials of combined modality therapy included patients with stage I and II disease as well as those with stage III disease. In addition, trials and subset analyses that focused on patients with stage III NSCLC did not consistently distinguish between those with IIIA or IIIB disease. These studies are further confounded by the wide range of T and N combinations that comprise stage III disease and the small size of most studies, which compromises subset analyses of specific T and N groupings.",
"     </li>",
"     <li>",
"      Clinical versus pathologic staging &mdash; Most older studies relied upon clinical categorization of stage III disease based on imaging studies rather than pathologic evaluation. The use of improved radiographic staging techniques such as PET and CT scanning, and routine pre-thoracotomy pathologic mediastinal evaluation permit a more accurate assessment of treatment effectiveness in homogenous populations and facilitate comparisons between different studies. Advances in minimally invasive staging techniques, such as endoscopic and bronchoscopic ultrasound-guided biopsy and video-assisted thoracoscopy, will further refine our ability to appropriately classify patients prior to enrollment on clinical trials. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/31/14841?source=see_link\">",
"       \"Diagnosis and staging of non-small cell lung cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/21/44373?source=see_link\">",
"       \"Tumor node metastasis (TNM) staging system for non-small cell lung cancer\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Recent improvements in imaging and pathologic evaluation that allow us to stage patients more accurately make it difficult to compare results of older and newer trials. As an example, PET scanning can identify hematogenous metastases in a substantial number of patients who have clinical stage III NSCLC when staged by traditional imaging methods. The removal of such patients with relatively minimal stage IV disease from the stage III category will induce a \"stage shift\" phenomenon with the potential to improve the apparent overall survival of populations of both stage III and IV patients.",
"     </li>",
"     <li>",
"      Change in the definition of stage III &mdash; In the 6th and 7th TNM staging system T3N0 lesions are classified as stage IIB rather than stage IIIA disease (",
"      <a class=\"graphic graphic_table graphicRef80099 \" href=\"mobipreview.htm?36/41/37533\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef74820 \" href=\"mobipreview.htm?19/43/20157\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/1\">",
"       1",
"      </a>",
"      ]. This reclassification removed the most favorable prognostic subgroup from stage IIIA and added a less favorable subgroup to stage IIB disease. As a result, studies using the 1997 staging system may appear to have a worse outcome for patients with both stage II and III disease compared with earlier reports. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Improvements in therapy &mdash; Major improvements in therapy limit the interpretation of early trials. As an example, the use of more active chemotherapy agents (eg, platinum derivatives, taxanes, targeted therapies and other third generation compounds) and refinements in RT delivery and surgical techniques have led to improvements in outcomes over time.",
"     </li>",
"     <li>",
"      Study design issues &mdash; Many early studies were inadequately powered to detect relatively small differences in therapeutic outcome. In others, the treated group was compared with historical controls rather than a concurrently treated, randomized control population. These problems were magnified by the publication of numerous preliminary reports with limited duration of follow-up that tended to overestimate the potential benefits of treatment, a situation that continues to impact on our ability to apply trial results to patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, primary surgical resection was used to treat nonbulky stage IIIA disease. However, the advent of routine pathologic staging of the mediastinum and the recognition of poor outcomes with primary surgery for patients with clinical stage IIIA disease have lessened the role of primary surgery in patients with stage III NSCLC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Resected stage IIIA disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection is the treatment of choice for patients who appear to have clinical stage I or II disease when pathological involvement of mediastinal lymph nodes is",
"    <strong>",
"     not",
"    </strong>",
"    detected preoperatively. Despite careful preoperative evaluation, including endobronchial ultrasound (EBUS)",
"    <span class=\"nowrap\">",
"     and/",
"    </span>",
"    or mediastinoscopy staging, mediastinal nodal involvement is identified in the final pathologic specimen in up to 20 percent of these patients with larger central lesions.",
"   </p>",
"   <p>",
"    For patients found to have such microscopic nodal disease in a resection specimen, recent studies have demonstrated that adjuvant chemotherapy can result in a significant survival benefit. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Adjuvant therapy in resected patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     T3N1 disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with tumors involving the chest wall or proximal airways (within 2 cm of the carina) with hilar, but not mediastinal, lymph node involvement are classified as stage IIIA (T3 N1), but they have a better prognosis than those who have stage IIIA disease due to N2 nodal involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. The appropriate initial management of these patients involves surgical resection, if technically feasible, followed by adjuvant chemotherapy for those with completely resected disease. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Adjuvant therapy in resected patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The only exception to this general principle is that superior sulcus (Pancoast) tumors with hilar lymph node involvement (T3-4 N1 M0) are generally treated with chemoradiotherapy followed by surgery. The management of Pancoast tumors is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/58/14250?source=see_link\">",
"     \"Pancoast's syndrome and superior (pulmonary) sulcus tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tumors more than 7 cm in size are now classified as T3 as in the 7th edition of the TNM system. When these large tumors are associated with N1 involvement, they are also considered stage IIIA. As per the T3N1 tumors mentioned above, the appropriate initial management of these patients involves surgical resection after negative invasive mediastinal staging, if technically feasible, followed by adjuvant chemotherapy for those with completely resected disease. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Adjuvant therapy in resected patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Separate tumor nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 7th TNM staging system (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"mobipreview.htm?36/41/37533\">",
"     table 1",
"    </a>",
"    ), tumor nodules in the same lobe as the primary are classified as T3, while nodules in another ipsilateral lobe are considered T4. Nodules in the contralateral lung are classified as M1a.",
"   </p>",
"   <p>",
"    Patients with T3N0 or T3N1 disease due to the presence of satellite nodules within the same lobe as the primary tumor are candidates for surgery as their initial treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Patients with ipsilateral nodules in another lobe and negative mediastinal nodes (IIIA, T4N0 or T4N1) may also be candidates for surgical resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/13,15,16\">",
"     13,15,16",
"    </a>",
"    ]. Adjuvant chemotherapy is often recommended in this setting, but data are limited for this patient subset. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Adjuvant therapy in resected patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although patients with solitary tumor nodules in each lung are considered stage IV, many of these patients actually have synchronous primaries and may have a very favorable outcome if treated aggressively. A reasonable approach in this setting is full radiographic staging, combined with mediastinoscopy. If that evaluation is negative, a presumption of synchronous unrelated cancers and treatment as such is reasonable in carefully selected cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H522757065\">",
"    <span class=\"h2\">",
"     T4N0-1 disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically, T4 lesions had been considered unresectable by definition and as a result, all T4 lesions used to be considered stage IIIB malignancies. With improvement in surgical techniques and in surgical care, however, carefully selected patients with carinal involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/16-18\">",
"     16-18",
"    </a>",
"    ], superior vena caval [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/19,20\">",
"     19,20",
"    </a>",
"    ] or vertebral body involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/21\">",
"     21",
"    </a>",
"    ] may benefit from surgery in the context of a multimodality approach. Survival rates up to 50 percent at five years have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/16,17,20\">",
"     16,17,20",
"    </a>",
"    ]. As a result, patients with T4N0-1 lesions have been reclassified as stage IIIA tumors in the 7th edition of the TNM system.",
"   </p>",
"   <p>",
"    These surgical T4N0-1 lesions are uncommon as most T4 lesions are not surgical and are best treated with definitive chemoradiation therapy. Patient selection is of critical importance. Surgery for T4 disease is contraindicated in the presence of N2 involvement (stage IIIB) or if an incomplete resection is inevitable. The surgeries required are demanding, the operative morbidity can be substantial, and the best results are definitely obtained in centers of excellence. Preoperative induction chemotherapy or chemoradiotherapy may be of value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/19,22\">",
"     19,22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Preoperative induction therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to its role in combined modality therapy and as adjuvant therapy following complete surgical resection, chemotherapy is the primary treatment for patients with malignant effusions. In the new staging system, malignant pleural effusion has now been categorized under \"M1a\" (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"mobipreview.htm?36/41/37533\">",
"     table 1",
"    </a>",
"    ). Most modern chemotherapy regimens are platinum based, although non-platinum combinations are an alternative in selected circumstances. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link\">",
"     \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with malignant pleural or pericardial effusions are generally considered incurable, and aggressive combined modality approaches are not indicated outside of a clinical trial. Patients are managed palliatively with interventions to control the effusion and systemic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/6/13416?source=see_link\">",
"     \"Management of malignant pleural effusions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/1/1050?source=see_link\">",
"     \"Pericardial disease associated with malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link\">",
"     \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TARGETED THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Agents that target the epidermal growth factor receptor (EGFR) pathway are now being studied in combination with chemotherapy and radiotherapy for patients with unresectable stage III NSCLC.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     Cetuximab",
"    </a>",
"    , a monoclonal antibody against the EGFR, has been successfully combined with radiotherapy in patients with head and neck cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29946?source=see_link\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     Cetuximab",
"    </a>",
"    has demonstrated promising efficacy in two phase II studies for stage III NSCLC in combination with radiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. A definitive phase III study is being conducted by the RTOG (RTOG 0617) to define the role for cetuximab in this setting (NCT00533949) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/25\">",
"     25",
"    </a>",
"    ]. This trial has met its accrual target and results are pending. Other molecularly targeted agents that have demonstrated promising activity in advanced NSCLC are in early phase clinical trials for stage III NSCLC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RADIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;RT alone is used as definitive treatment for patients with unresectable stage III NSCLC who are not candidates for combined modality therapy. RT also has a role in carefully selected patients with isolated thoracic recurrence after previous therapy and as palliative treatment for those with poor performance status. (See",
"    <a class=\"local\" href=\"#H102893541\">",
"     'Poor performance status patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Definitive RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive RT was the treatment of choice for patients with unresectable stage III NSCLC until clinical trials demonstrated improved survival with combined modality therapy. RT without chemotherapy remains the preferred approach for poor-risk patients who are not candidates for combined modality therapy. The benefits of RT include palliation of tumor-related symptoms, local control of tumor growth, and possibly a survival advantage. An early randomized trial suggested that RT (40 to 50 Gy) provided a modest, but significant, survival advantage at one year compared to patients not receiving RT (18 versus 14 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of RT alone for patients with stage III NSCLC consistently results in a median survival of about 10 months and five-year survival rates of around 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. Factors associated with an improved prognosis following definitive RT include small primary tumor and limited total tumor volumes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Dose and local control",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 1970s, the Radiation Therapy Oncology Group (RTOG) performed a phase III trial to evaluate the influence of RT dose on outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/31\">",
"     31",
"    </a>",
"    ]. Patients were randomly assigned to treatment with 40, 50, or 60 Gy in 2 Gy daily fractions. Local control rates were significantly better with the highest dose (52, 62, and 73 percent, respectively), although survival was similar. This study established 60 Gy in 30 daily fractions as the standard RT dose-fractionation schema.",
"   </p>",
"   <p>",
"    A contemporary phase III trial (RTOG 0617) randomly assigned patients with stage III NSCLC to one of two chemotherapy regimens and to either standard dose RT (60",
"    <span class=\"nowrap\">",
"     Gy/30",
"    </span>",
"    daily fractions) or high dose (74",
"    <span class=\"nowrap\">",
"     Gy/37",
"    </span>",
"    daily fractions). RT was given either with 3D conformal techniques or by IMRT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/32\">",
"     32",
"    </a>",
"    ]. A preliminary report of the analysis comparing the two RT regimens used in this trial found no evidence of improved survival with the higher dose of RT.",
"   </p>",
"   <p>",
"    Based upon the results of this trial, the standard dose of RT for stage III NSCLC remains 60 Gy. Other approaches that may improve the therapeutic index remain under study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Altered fractionation schedules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple trials have explored the use of altered dose fractionation schedules in order to improve the therapeutic index of RT for NSCLC. These approaches include hyperfractionation (two or three fractions per day with a lower dose per fraction over the standard treatment duration), accelerated fractionation (using a standard fraction size and total radiation dose, given over a shorter overall time), or a combination of hyperfractionation and acceleration.",
"   </p>",
"   <p>",
"    The most extensive information comes from a meta-analysis that incorporated individual patient data from 2000 patients in eight randomized trials, in which patients were randomly assigned to an altered regimen or conventional fractionation (five daily fractions per week of 1.8 to 2.0 Gy, with a minimum dose of 60 Gy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/33\">",
"     33",
"    </a>",
"    ]. The analysis included 1637 patients with stage III NSCLC. The analysis was limited to trials in which chemotherapy was identical in both treatment arms.",
"   </p>",
"   <p>",
"    Modified fractionation resulted in a small, but statistically significant, improvement in overall five-year survival (10.8 versus 8.3 percent; hazard ratio 0.88, 95% CI 0.80-0.97); there were no significant differences in outcomes between patients with stage",
"    <span class=\"nowrap\">",
"     I/II,",
"    </span>",
"    IIIA, and IIIB NSCLC. However, the modified fractionation schedules resulted in a significantly increased risk of severe esophageal toxicity (19 versus 9 percent, odds ratio 2.44).",
"   </p>",
"   <p>",
"    More studies are required to address which RT regimen is best administered with concurrent chemotherapy. Modified RT schedules remain less commonly utilized than a conventional once daily radiation plan, due in part to the logistical challenges for patients and treating centers, as well as the increased toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Isolated thoracic recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The five-year survival rates following surgical resection for stage I and stage II NSCLC range from 60 to 75 percent and 36 to 60 percent, respectively. Approximately one-third of patients who relapse initially have an isolated recurrence in the ipsilateral thorax [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/5/1114?source=see_link&amp;anchor=H23#H23\">",
"     \"Management of stage I and stage II non-small cell lung cancer\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    RT, alone or with chemotherapy, may salvage carefully selected patients with an isolated thoracic recurrence following surgery. This was illustrated in a retrospective, single-institution series of 29 patients treated over a 13 year period with definitive RT (median dose 66 Gy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/35\">",
"     35",
"    </a>",
"    ]. Mediastinal lymphadenopathy was present in 19 patients, seven had disease confined to the surgical stump, and three had hilar lymphadenopathy. The actuarial rate of local control was 62 percent at two years and the two-year overall survival rate was 38 percent. Most subsequent relapses were at distant sites. Five patients were alive without evidence of disease at 22 to 158 months following RT.",
"   </p>",
"   <p>",
"    A review of seven earlier series that included 243 patients treated with RT for isolated thoracic recurrence found that median survival ranged from 11 to 19 months and two-year survival rates from 10 to 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with an isolated thoracic recurrence after surgical resection, further resection should be considered if the recurrence is in a stage I or II pattern and the patient can tolerate further surgery. For those with a stage I or II pattern of recurrence who are not candidates for further resection, radiotherapy alone is a reasonable salvage treatment option. For patients with a recurrence in a stage III pattern of disease, definitive chemotherapy plus radiotherapy should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Palliative RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shorter courses of RT (eg, 30 Gy in 10 fractions) are useful for the palliation of thoracic symptoms (eg, dysphagia, hemoptysis, or dyspnea due to airway obstruction) in patients who are not candidates for more aggressive therapy, such as those with poor performance status or very advanced age, or those who relapse after their initial treatment. The use of palliative RT is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/36/40520?source=see_link&amp;anchor=H16#H16\">",
"     \"Second-line therapy for patients with previously treated advanced non-small cell lung cancer\", section on 'Symptom palliation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An important clinical question in asymptomatic patients who are not candidates for combined modality therapy is whether RT should be administered immediately or deferred until symptoms develop. This question was directly addressed in a British trial in which 230 patients with minimally symptomatic, unresectable NSCLC were randomly assigned to immediate RT or supportive care with RT reserved until symptoms developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Median survival was not significantly different in those receiving immediate RT compared with delayed RT (8.3 versus 7.9 months, respectively), and the rate of symptom control was similar. The treatment intent in this trial was palliation rather than cure and these survival times are grossly inferior to recent trial results using immediate chemoradiotherapy. Overall, we recommend immediate rather than deferred treatment whenever possible. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Concurrent chemoradiotherapy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link\">",
"     \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive RT (approximately 60 Gy in 30 daily fractions) is an important alternative approach for patients with stage III NSCLC who are not candidates for combined modality treatment. The role of altered RT fractionation schedules remains uncertain and its use is largely restricted to the clinical trial setting. Definitive RT also has a role in carefully selected patients with isolated thoracic recurrence after previous surgical resection. Shorter courses of palliative RT are valuable for symptomatic patients with a poor performance status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ADJUVANT THERAPY IN RESECTED PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with completely resected stage III NSCLC are at a high risk for both local and distant failure, providing a rationale for postoperative RT and adjuvant chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Postoperative RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of postoperative RT in patients with completely resected stage III NSCLC remains uncertain, and may be influenced by the extent of nodal involvement (N1 or N2) and the use of adjuvant chemotherapy.",
"   </p>",
"   <p>",
"    Although initial retrospective series suggested improvements in survival as well as local control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/37\">",
"     37",
"    </a>",
"    ], a survival benefit was not confirmed in randomized trials. In a 1998 meta-analysis that included 2128 patients enrolled in nine randomized trials evaluating postoperative RT, adjuvant RT was associated with an inferior outcome (21 percent relative increase in the risk of death, which translated into a 7 percent absolute reduction in two-year survival) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/38\">",
"     38",
"    </a>",
"    ]. However, in subgroup analysis, the detrimental effect on survival was limited to patients with stage I or II disease, whereas there was no clear evidence of either an adverse or a beneficial effect for those with stage III disease.",
"   </p>",
"   <p>",
"    The results of this meta-analysis are subject to several important limitations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/39\">",
"     39",
"    </a>",
"    ]. As an example, the RT techniques (eg, cobalt machines, single RT field) used in many of the trials are not consistent with current standards and more than 30 percent of the patients included in the meta-analysis came from a single study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/40\">",
"     40",
"    </a>",
"    ] in which large dose fractions (2.5 Gy) and high total doses (up to 60 Gy) were permitted, an approach that may have increased toxicity, thereby biasing the outcome of the meta-analysis.",
"   </p>",
"   <p>",
"    Two subsequent analyses from the Surveillance, Epidemiology and End Results (SEER) database evaluated the role of extent of disease on survival after postoperative RT and the effect of radiation technique on cardiac toxicity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An analysis of 7465 patients with stage II or III NSCLC (",
"      <a class=\"graphic graphic_table graphicRef80099 \" href=\"mobipreview.htm?36/41/37533\">",
"       table 1",
"      </a>",
"      ) between 1988 and 2002 found that patients with N0 or N1 disease had a significantly decreased five-year survival rate with postoperative RT (31 versus 41 percent with observation for those with N0 disease; 30 versus 34 percent for those with N1 disease) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/41\">",
"       41",
"      </a>",
"      ]. In contrast, patients with N2 lymph node involvement had a significantly improved five-year survival rate with adjuvant RT (27 versus 20 percent, p = 0.0077).",
"     </li>",
"     <li>",
"      Cardiac toxicity from RT may have contributed to mortality in early studies using postoperative RT. In an analysis of 6148 patients who underwent surgical resection followed by postoperative RT, the risk of death from heart disease was significantly higher in patients diagnosed from 1983 to 1988 (hazard ratio [HR] 1.49, 95% CI 1.11-2.01), but not in those diagnosed from 1989 to 1993 (HR 1.08, 95% CI 0.79-1.48) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/42\">",
"       42",
"      </a>",
"      ]. The decline in cardiac toxicity over time may have resulted from technical improvements in the planning and delivery of thoracic radiotherapy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/21/34137?source=see_link\">",
"       \"Cardiotoxicity of radiation therapy for malignancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Results from the phase III ANITA trial, which evaluated adjuvant chemotherapy in patients with completely resected stage IB-IIIA NSCLC, suggest that the effect of postoperative RT is affected both by the extent of nodal involvement and the use of adjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Formal statistical comparisons were not performed because of the nonrandomized nature of this subset analysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17833?source=see_link&amp;anchor=H13#H13\">",
"     \"Adjuvant systemic therapy in resectable non-small cell lung cancer\", section on 'ANITA'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with N2 disease, survival was longer in patients who received postoperative RT than in those not given RT (median 47 versus 24 months in those given adjuvant chemotherapy and 23 versus 13 months in those not given adjuvant chemotherapy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/44\">",
"     44",
"    </a>",
"    ]. In contrast, for those with N1 disease, RT had a negative effect on survival in those given adjuvant chemotherapy (47 versus 94 months) but a positive effect in those not receiving chemotherapy (50 versus 26 months).",
"   </p>",
"   <p>",
"    Postoperative RT is commonly used in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with positive resection margins",
"     </li>",
"     <li>",
"      Postoperative RT may also be considered for patients with inadequate lymph node sampling in whom mediastinal node involvement was suspected but not confirmed. The use of PORT in this scenario should not be prioritized over that of adjuvant chemotherapy.",
"     </li>",
"     <li>",
"      For patients with involvement of multiple stations of involved N2 lymph nodes (following administration of adjuvant chemotherapy)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, prospective randomized trials documenting the effectiveness of postoperative RT in these situations are needed. The ongoing",
"    <span class=\"nowrap\">",
"     EORTC/IFCT",
"    </span>",
"    LUNG ART trial in Europe is evaluating the role of sequential PORT in patients with completely resected N2 disease who have received pre or postoperative adjuvant chemotherapy (NCT00410683) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Adjuvant chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjuvant chemotherapy has been extensively evaluated in an attempt to decrease the incidence of distant metastases and improve long-term survival. Although early clinical trials did not demonstrate a survival benefit, three separate meta-analyses suggested that systemic treatment following surgery for stage I to III NSCLC produced a modest, but significant, with a 4 to 5 percent absolute improvement in five-year survival. More recent clinical trials utilizing modern platinum-based doublet regimens have confirmed a survival benefit and suggested that the magnitude of benefit may be even larger than suggested in the meta-analyses. Although results have differed according to stage in various trials, the weight of evidence suggests that adjuvant chemotherapy benefits patients with completely resected stage II and III disease.",
"   </p>",
"   <p>",
"    The results of specific clinical trials and the use of adjuvant chemotherapy in NSCLC is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17833?source=see_link\">",
"     \"Adjuvant systemic therapy in resectable non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adjuvant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy is now considered the standard of care for patients with completely resected stage II and III NSCLC. Both the National Comprehensive Cancer Network and the American Society of Clinical Oncology have amended their treatment guidelines for NSCLC to recommend cisplatin-based regimens in patients with resected stage II or III disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Adjuvant chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recent positive results with adjuvant chemotherapy and the high rate of local failure following surgery in patients with stage III NSCLC have prompted an interest in adjuvant chemoradiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/48\">",
"     48",
"    </a>",
"    ]. Thus far, trials that have evaluated adjuvant chemotherapy plus postoperative RT have utilized a sequential approach and, as noted above, the role of RT in the postoperative setting remains unproven. At this time, there are no data to support the use of adjuvant concurrent chemoradiotherapy in patients with totally resected stage IIIA disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/5/1114?source=see_link&amp;anchor=H21#H21\">",
"     \"Management of stage I and stage II non-small cell lung cancer\", section on 'Postoperative RT'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17833?source=see_link\">",
"     \"Adjuvant systemic therapy in resectable non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If RT is planned for the postoperative setting, RT should be given after completion of adjuvant chemotherapy, since a concurrent approach might compromise the ability to deliver recommended dose and cycles of chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Prophylactic cranial irradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with stage III NSCLC are at high risk for the subsequent development of brain metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. In a retrospective analysis of 422 patients, brain metastases developed in 26 percent and were more common in those less than 60 years of age or with nonsquamous histology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/49\">",
"     49",
"    </a>",
"    ]. These results suggest a possible role for prophylactic cranial irradiation (PCI), as is used for small cell lung cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/50/1830?source=see_link\">",
"     \"Prophylactic cranial irradiation for patients with small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three prospective randomized trials conducted in the 1970s and 1980s suggested that PCI reduced the frequency of brain metastases in patients with advanced NSCLC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. A systematic review that was based upon these trials concluded that PCI may reduce the incidence of brain metastases, but does not improve survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/55\">",
"     55",
"    </a>",
"    ]. Two subsequent randomized trials also observed a decrease in the frequency of brain metastases without an improvement in overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Radiation Therapy Oncology Group conducted the largest trial in this setting (RTOG 0214), in which patients with stage III NSCLC were randomly assigned to PCI (30 Gy in 15 fractions) or observation following initial therapy with surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thoracic RT with or without chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Because of slow accrual, only 356 of a planned 1058 patients were enrolled. Long-term follow-up may be useful.",
"   </p>",
"   <p>",
"    Key findings from the RTOG 0214 trial included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of brain metastases was significantly decreased with PCI compared to observation (one-year rate 7.7 versus 18.0 percent).",
"     </li>",
"     <li>",
"      The study was not adequately powered due to incomplete accrual but there was no statistically significant improvement in the one-year disease-free survival and overall survival rates with PCI compared to observation (56 versus 51 percent and 76 versus 77 percent, respectively).",
"     </li>",
"     <li>",
"      Assessment of quality of life and global cognitive function did not reveal any impairment associated with PCI. However, there was a significant decline memory at one year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An analysis of the trial results with a follow-up of almost five years showed no difference in overall survival (five-year rate 26 versus 25 percent for PCI and observation, respectively) although there was a decreased incidence of brain metastases (five-year rate 17 versus 27 percent for PCI and observation) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PCI cannot be recommended at this time for stage III NSCLC outside the setting of a clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF POTENTIALLY RESECTABLE STAGE III DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The high rate of both local and distant failure with resection alone provides the rationale for a combined modality approach with or without surgery in patients with unresected stage III disease. When pathologic involvement of mediastinal lymph nodes is documented prior to surgical resection, a combined modality approach is recommended. A number of options have been evaluated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preoperative induction therapy, with chemotherapy alone, RT alone, or chemoradiotherapy",
"     </li>",
"     <li>",
"      Definitive chemotherapy and radiation therapy, either using sequential chemotherapy followed by RT or concurrent chemoradiotherapy, or induction chemotherapy followed by chemoradiotherapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     PREOPERATIVE INDUCTION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction (neoadjuvant) therapy refers to the use of chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    RT prior to surgery. This approach carries several theoretical advantages:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A decrease in tumor volume, resulting in better local control with subsequent treatment",
"     </li>",
"     <li>",
"      Relatively high response rates to chemotherapy in patients with stage III as compared to those with stage IV NSCLC",
"     </li>",
"     <li>",
"      Earlier treatment of micrometastatic disease",
"     </li>",
"     <li>",
"      Better tolerance of and compliance with preoperative chemotherapy compared with adjuvant chemotherapy after surgery",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Induction chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials comparing induction (neoadjuvant) chemotherapy followed by surgery versus immediate surgery have demonstrated a modest survival advantage for induction therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two randomized trials limited to patients with stage IIIA NSCLC examined this issue. Both studies were stopped early with only 60 patients enrolled, and both found a statistically significant survival advantage associated with the use of induction chemotherapy prior to surgery compared to immediate surgery (median survival: 8 versus 26 months; 11 versus 64 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/60,62\">",
"     60,62",
"    </a>",
"    ]. Postoperative RT was given to all patients in one of the trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/60\">",
"     60",
"    </a>",
"    ], and approximately one-half of patients in the other [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/62\">",
"     62",
"    </a>",
"    ]. In both of these studies, the magnitude of the benefit diminished with longer follow-up (median survival: 10 versus 22 months; 14 versus 21 months). The major limitations of these trials are their small sample size and the use of surgery alone, a suboptimal therapy for patients with clinical stage IIIA disease, as a control arm. This latter point is clearly illustrated by a five-year survival rate of 0 percent in the immediate surgery arm of one of these trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, several larger trials that compared immediate surgery versus a neoadjuvant approach have found either no benefit or a benefit that was limited to patients with stage I and stage II disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/63\">",
"     63",
"    </a>",
"    ]. The role of neoadjuvant chemotherapy compared to immediate surgery is discussed in further detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17833?source=see_link&amp;anchor=H20#H20\">",
"     \"Adjuvant systemic therapy in resectable non-small cell lung cancer\", section on 'Neoadjuvant chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In routine practice, either chemotherapy alone followed by surgery or chemoradiotherapy followed by surgery is used for patients with potentially resectable stage III disease. Induction chemotherapy may be appropriate in patients with relatively low-volume mediastinal disease or microscopic N2 disease. An Intergroup trial that compared induction chemotherapy alone to chemoradiotherapy, followed by surgical resection in patients with biopsy-proven stage IIIA-N2 NSCLC was closed due to poor accrual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Preoperative radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative RT has been studied as a means of increasing surgical resectability in patients with locally advanced disease. Although older studies suggested a benefit for this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/64,65\">",
"     64,65",
"    </a>",
"    ], it was not confirmed in a later randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/66\">",
"     66",
"    </a>",
"    ]. Preoperative RT has been largely abandoned in favor of chemoradiotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Preoperative chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Definitive concurrent chemoradiotherapy is the preferred approach for patients with unresectable stage III NSCLC, based upon superior survival compared to RT alone or to sequential chemotherapy and RT (see",
"    <a class=\"local\" href=\"#H32\">",
"     'Concurrent chemoradiotherapy'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Despite improvements in survival with concurrent chemoradiotherapy, there is still a high incidence of locoregional failure. This pattern of failure has raised the question of whether surgical resection after neoadjuvant chemoradiotherapy can add a further survival advantage to definitive chemoradiotherapy alone. Although uncontrolled phase II studies suggested a survival benefit from surgery after neoadjuvant chemoradiotherapy (",
"    <a class=\"graphic graphic_table graphicRef74848 \" href=\"mobipreview.htm?22/37/23133\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/22,48,67-77\">",
"     22,48,67-77",
"    </a>",
"    ], reports of two large randomized phase III trials have not confirmed a significant survival advantage for surgery following either neoadjuvant concurrent chemoradiotherapy or induction chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intergroup 0139 &mdash; In the Intergroup 0139 trial, 429 potentially resectable patients with biopsy-proven stage IIIA-N2 NSCLC were randomly assigned to either concurrent RT (45 Gy) plus chemotherapy for two cycles of PE (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      days 1, 8, 29, and 35 plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      days 1 to 5, and 29 to 33) followed by surgical resection followed by two further cycles of PE chemotherapy or to concurrent RT to 61 Gy with four cycles of PE chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/78\">",
"       78",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In a planned interim analysis, the use of surgery was associated with a sevenfold increase in the control of the primary tumors and a significant increase in five-year progression-free survival (PFS, 22 versus 11 percent), but only a non-significant trend toward better overall survival (five-year survival rate 27 versus 20 percent). An increase in early mortality associated with surgery, particularly in patients undergoing pneumonectomy (26 percent postoperative mortality), may have negated a potential benefit of resection. [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/80,81\">",
"       80,81",
"      </a>",
"      ] Although the observed mortality is higher than reported by centers of excellence, it highlights the importance of thoracic surgery expertise in the trimodality management of stage IIIA patients. In a secondary subset analysis, patients treated with lobectomy after induction therapy appeared to do significantly better than a matched group of control patients treated with definitive chemoradiotherapy alone without surgery. &nbsp;",
"     </li>",
"     <li>",
"      EORTC 08941 &mdash; In a phase III trial investigating the role of surgery versus RT after induction chemotherapy, 579 patients with biopsy-proven unresectable stage IIIA-N2 NSCLC received three cycles of platinum-based chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/79\">",
"       79",
"      </a>",
"      ]. Nonprogressors were then randomized to surgery (n = 167) or thoracic RT (n = 165).",
"      <br/>",
"      <br/>",
"      Median survival and five-year overall survival rates were similar (16.4 versus 17.5 months and 16 versus 14 percent for the surgery and RT groups, respectively; HR 1.06, 95% CI 0.84-1.35). A major criticism of this trial is that only 50 percent of patients randomized to surgical resection achieved a complete resection. The operative mortality of patients who underwent pneumonectomy after induction chemotherapy however was much more acceptable at 7 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus far, there are little data to support the use of neoadjuvant chemotherapy followed by surgery over definitive concurrent chemoradiotherapy in patients with stage IIIA-N2 NSCLC. Two European trials have attempted to compare the approach of induction chemotherapy alone to that of an induction chemoradiation therapy strategy and neither have shown the superiority of one approach over the other [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/82,83\">",
"     82,83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether surgical resection after induction chemoradiotherapy adds a survival benefit to definitive chemoradiotherapy alone remains uncertain, though this approach may be reasonable for selected, otherwise healthy patients with non-bulky mediastinal lymph node involvement whose primary tumor can be resected with a lobectomy.",
"   </p>",
"   <p>",
"    Patients who required a pneumonectomy in the Intergroup 0139 study had an unacceptable mortality following induction chemoradiotherapy. Although some centers have reported less surgery-related mortality, consideration of pneumonectomy in this setting should generally be restricted to a clinical trial setting and to surgeons in centers of excellence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/80,84,85\">",
"     80,84,85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF SURGICALLY UNRESECTABLE STAGE III DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, tumors that directly invade the mediastinum, major blood vessels, vertebral column, trachea, esophagus or the heart were historically considered surgically unresectable and most such tumors are indeed nonsurgical, with the exception of a few selected patients with T4 disease. Surgery for such tumors should only be entertained and undertaken by surgeons with the appropriate expertise in select centers of excellence. (See",
"    <a class=\"local\" href=\"#H522757065\">",
"     'T4N0-1 disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients with pathological involvement of N2 nodes that are bulky or involve multiple stations and N3 nodes are treated with definitive combined modality approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     DEFINITIVE CHEMOTHERAPY AND RADIATION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy and RT have been combined in an effort to treat both locoregional and micrometastatic disease in patients with unresectable stage III NSCLC. Initially, sequential therapy (chemotherapy followed by RT) was used to avoid overlapping toxicities, and clinical trials established the benefits of this approach compared to RT alone. Subsequent studies comparing sequential versus concurrent chemoradiotherapy have demonstrated a survival benefit for the concurrent approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Sequential chemotherapy and radiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two cooperative group trials and two meta-analyses established that sequential chemotherapy followed by RT improved survival compared with definitive RT alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/27,28,86-88\">",
"     27,28,86-88",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In Cancer and Leukemia Group B (CALGB) trial 8433, 155 patients with stage III NSCLC were randomly assigned to RT alone (60 Gy over six weeks) or two cycles of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based chemotherapy followed by the same RT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/27\">",
"       27",
"      </a>",
"      ]. With seven-year follow-up, the addition of chemotherapy was associated with significantly better median and five-year survival (14 versus 10 months and 17 versus 6 percent).",
"     </li>",
"     <li>",
"      These results were confirmed in a subsequent Intergroup trial, which randomly assigned 452 patients with stage III disease to conventional RT (60 Gy in 30 daily fractions) hyperfractionated RT (69.6 Gy in 58 fractions of 1.2 Gy each, given twice daily), or chemotherapy (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ) followed by conventional RT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/28,86\">",
"       28,86",
"      </a>",
"      ]. The overall survival with sequential chemotherapy and RT was significantly better than with either conventional or hyperfractionated RT alone (median survival, 13.2 versus 11.4 and 12 months, respectively). The observed differences in survival rates were greater at two years (32 versus 19 and 24 percent, respectively) than at five years (8, 5, and 6 percent, respectively) with sequential chemoradiotherapy, conventional RT alone, and hyperfractionated RT alone, respectively.",
"     </li>",
"     <li>",
"      Two meta-analyses of trials comparing sequential chemoradiotherapy versus RT alone or chemotherapy alone also concluded that one- and two-year survival rates were better with the combined approach, but that this short-term survival benefit did not translate into better long-term outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/87,88\">",
"       87,88",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Concurrent chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concurrent administration of chemotherapy and radiotherapy provides early treatment of micrometastatic disease and exploits the synergistic effect of chemotherapy and RT to enhance local tumor eradication. Randomized trials have established the superiority of this approach compared with sequential chemotherapy and RT, and concurrent chemoradiotherapy has become the preferred approach for most patients with unresected pathologic stage IIIA and IIIB disease (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Staging'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Initial concerns about the toxicity of full doses of chemotherapy during RT led to the use of reduced doses (see",
"    <a class=\"local\" href=\"#H34\">",
"     'Elderly patients'",
"    </a>",
"    below). However, subsequent studies showed that full-dose chemotherapy could be given concurrently with manageable toxicity, and this has become the standard approach for concurrent chemoradiotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Standard-dose chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The superiority of concurrent chemoradiotherapy compared with sequential chemotherapy and RT has been demonstrated in a meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/89\">",
"     89",
"    </a>",
"    ] and is illustrated by the results of two large, multicenter, randomized phase III trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/90-92\">",
"     90-92",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radiation Therapy Oncology Group (RTOG) trial 9410, a three-arm trial which included 610 patients with unresected stage III disease, compared sequential",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/3/4152?source=see_link\">",
"       vinblastine",
"      </a>",
"      for two cycles followed by conventional RT (60 Gy in 30 fractions) with two cycles of the same regimen administered concurrently with conventional RT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/90\">",
"       90",
"      </a>",
"      ]. A third study arm evaluated concurrent cisplatin plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      with twice daily RT to a total dose of 69.6 Gy.",
"      <br/>",
"      <br/>",
"      With over 95 percent of patients followed until death, concurrent chemoradiotherapy with conventional RT fractionation was superior to sequential chemoradiotherapy (median survival 17.0 versus 14.6 months, hazard ratio for death 0.81, 95% CI 0.663-0.996). The difference between the conventional fractionation chemoradiotherapy and twice daily regimen was not statistically significant (median survival 17.0 versus 15.6 months). Acute grade 3 or higher nonhematologic toxicity was more frequent with the concurrent regimens, but late toxicity rates were similar.",
"     </li>",
"     <li>",
"      In a Japanese study, 320 patients with unresectable stage III NSCLC were randomly assigned to either concurrent chemotherapy (two cycles of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31123?source=see_link\">",
"       vindesine",
"      </a>",
"      ) plus split-course thoracic RT (two courses of 28 Gy in 2 Gy daily fractions, separated by ten days) or to two cycles of the same chemotherapy regimen followed by a single course of RT (56 Gy in 28 fractions) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/91,92\">",
"       91,92",
"      </a>",
"      ]. Despite the use of a split-course RT schedule, concurrent therapy was associated with a significantly better response rate (84 versus 66 percent), median survival (17 versus 13 months), and two- and five-year survival rates (35 versus 27 percent and 16 versus 9 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The optimal chemotherapy regimen for use with concurrent thoracic radiotherapy is not known due to a paucity of randomized trials comparing different chemotherapy regimens in the stage III setting. Some regimens may be associated with increased incidence of pulmonary toxicity. As an example, in a study of 19 patients treated with concurrent chemoradiotherapy using a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    regimen, six patients (32 percent) developed high-grade radiation pneumonitis, one of whom died [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The two chemotherapy regimens that have been most commonly used in the US are the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    and the weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    regimens. More recently, use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    plus cisplatin (or occasionally carboplatin) has increased as well, particularly in patients with nonsquamous NSCLC. Two phase II studies by the Southwest Oncology Group (SWOG) utilized two cycles of concurrent cisplatin plus etoposide with concurrent once daily chest RT to approximately 60 Gy. In these trials, concurrent chemoradiotherapy was followed by additional cycles of cisplatin plus etoposide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/94\">",
"     94",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of concurrent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1, 8, 29, and 36) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily on days 1 to 5, and 29 to 33) with thoracic RT followed by consolidation cisplatin plus etoposide was shown in a multicenter phase II trial of 50 patients with pathologically confirmed stage IIIB disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/94\">",
"     94",
"    </a>",
"    ]. With an average follow-up of 52 months, the three- and five-year survival rates were 17 and 15 percent, respectively. Treatment was complicated by grade 4 neutropenia in 32 percent and grade 3 or 4 esophagitis in 20 percent of patients. In a subsequent phase II trial, better results were seen with the same concurrent chemoradiation regimen followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    consolidation, but the use of consolidation chemotherapy in this setting has been called into question by more recent data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/95,96\">",
"     95,96",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H36\">",
"     'Consolidation therapy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/42/20137?source=see_link&amp;anchor=H2#H2\">",
"     \"Gastrointestinal toxicity of radiation therapy\", section on 'Esophagitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another approach used for the combined modality setting involves the weekly chemotherapy regimen of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    given with radiotherapy. In a large phase II randomized study, carboplatin (AUC = 2) and paclitaxel (45",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    given weekly with radiotherapy (63 Gy) followed by two cycles of consolidation therapy (carboplatin AUC = 6, paclitaxel 200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    was associated with a median survival of 16.3 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/97\">",
"     97",
"    </a>",
"    ]. This regimen has a favorable tolerability profile and has been found suitable for combination with targeted agents or the use of higher dose of radiotherapy.",
"   </p>",
"   <p>",
"    The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    has also demonstrated promising safety and efficacy results in phase II studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/98\">",
"     98",
"    </a>",
"    ]. This regimen is being studied in a phase III study for patients with non-squamous NSCLC. Like the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    regimen, the carboplatin-pemetrexed combination can be given in regular systemic doses in combination with radiotherapy.",
"   </p>",
"   <p>",
"    Although concurrent chemoradiotherapy with platinum-based chemotherapy is associated with increased acute toxicity, the results are superior to those with sequential chemoradiotherapy. Thus, concurrent use of chemotherapy and definitive RT has become the preferred approach for patients with stage III NSCLC with mediastinal lymph node involvement or unresectable T3 or T4 lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Elderly patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-half of patients with NSCLC are 70 years of age or older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]. Although the majority of patients enrolled in multicenter trials are substantially younger, trials using standard doses of chemotherapy with concurrent RT have included carefully selected elderly patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/101-103\">",
"     101-103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One randomized trial and other observational analyses suggest that aggressive combined modality therapy can be beneficial in selected elderly patients, although it is associated with an increase in toxicity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a Japanese trial, 200 patients older than 70 years with unresectable stage III NSCLC were randomly assigned to chemoradiotherapy with RT plus concurrent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/m2,",
"      </span>",
"      five days per week for four weeks) or RT alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/104\">",
"       104",
"      </a>",
"      ]. RT consisted of 60 Gy in 30 fractions over six weeks for both groups. At a median follow-up of 19 months, the combined modality approach significantly prolonged overall survival (median 22 versus 17 months, HR 0.68, 95% CI 0.47-0.98). The addition of carboplatin to RT was associated with grade 3 or 4 leukopenia, neutropenia, and thrombocytopenia in 64, 57, and 29 percent of cases, respectively.",
"     </li>",
"     <li>",
"      A subset analysis of elderly patients from two randomized trials compared 37 patients treated with RT alone with 129 treated with RT plus a regimen of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/105\">",
"       105",
"      </a>",
"      ]. The median survival was significantly longer in patients treated with a combined modality approach (13.7 versus 10.5 months with RT alone), as was the five-year survival (15 versus 5 percent). However, the incidence of severe toxicity was also significantly increased (90 versus 32 percent).",
"     </li>",
"     <li>",
"      In a secondary analysis of a trial using concurrent chemoradiotherapy with full doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , and two different RT schedules, efficacy and toxicity were evaluated based upon whether or not patients were older than 70 years of age (26 percent of 246 patients) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/101\">",
"       101",
"      </a>",
"      ]. Combined modality therapy was associated with a significantly increased incidence of grade 4 toxicity in the older patients compared to the younger patients (81 versus 62 percent), but the two- and five-year survival rates were similar in the older and younger cohorts (36 versus 39 and 13 versus 18 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These analyses of multicenter trials have focused on elderly patients with particularly good performance status. Based upon these data, a combined modality treatment with standard-dose chemotherapy is an appropriate consideration for good-risk, \"fit\" elderly patients.",
"   </p>",
"   <p>",
"    However, the findings may not be applicable to patients with an impaired performance status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/100\">",
"     100",
"    </a>",
"    ]. Furthermore, elderly patients treated with chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy may be at increased risk of cardiac disorders, even if they were free of such problems prior to the diagnosis of NSCLC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Special considerations for the use of chemotherapy in the elderly population are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41864?source=see_link\">",
"     \"Comprehensive geriatric assessment for patients with cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=see_link\">",
"     \"Systemic chemotherapy for cancer in elderly persons\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Induction chemotherapy followed by chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of induction chemotherapy prior to concurrent chemoradiotherapy was associated with increased toxicity, but no survival advantage, in a phase III trial conducted by the CALGB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/107\">",
"     107",
"    </a>",
"    ]. In this study, patients were randomized to receive two cycles of induction therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    following by chemoradiotherapy versus chemoradiotherapy alone for surgically unresectable stage III disease. The median survival was 14 months with the induction approach and 12 months with chemoradiotherapy alone, but the differences were not statistically significant. The two-year survival rates were similar for the two treatment arms (29 and 31 percent, respectively). Radiation-related toxicities were not different between the two approaches. There was a slight imbalance in the distribution of patients with major weight loss between the two treatment arms that could have influenced the overall results of the study. Consequently, the induction approach is not used in routine practice for the treatment of locally advanced NSCLC.",
"   </p>",
"   <p>",
"    However, induction chemotherapy prior to definitive therapy may be required if the tumor cannot be encompassed in a safe RT treatment portal without an unacceptably high risk of radiation pneumonitis. In such cases, chemoradiotherapy or definitive RT alone can be administered subsequently if an adequate response to the induction chemotherapy is obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Consolidation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although consolidation chemotherapy may be feasible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/95,97,108-110\">",
"     95,97,108-110",
"    </a>",
"    ], randomized clinical trials have not demonstrated a survival advantage for consolidation chemotherapy after definitive chemoradiotherapy.",
"   </p>",
"   <p>",
"    The largest trial that directly addressed the effectiveness of consolidation chemotherapy was conducted by the Hoosier Oncology Group (HOG LUN 01-24) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/96,111\">",
"     96,111",
"    </a>",
"    ]. The trial enrolled 243 patients with stage IIIA or IIIB NSCLC (41 and 59 percent, respectively). After completion of RT and concurrent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , 166 patients were randomly assigned to three cycles of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    consolidation or to observation. The trial was stopped early based upon a planned interim analysis that met the predefined rule for futility.",
"   </p>",
"   <p>",
"    For all patients eligible for randomization after induction chemotherapy, the median overall survival was 25 months, and there was no difference between those managed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    consolidation and those assigned to observation (median overall survival 24 versus 26 months, and five-year survival rate 16 versus 24 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/111\">",
"     111",
"    </a>",
"    ]. Similarly, there was no difference in progression-free survival with or without consolidation docetaxel (median 10.8 versus 10.3 months). However, toxicity was significantly increased with docetaxel consolidation, as manifested by a higher incidence of hospitalization, pneumonitis, and treatment-related death (29 versus 8 percent with observation, 9.6 versus 1.4 percent, and 5.5 versus 0 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/96\">",
"     96",
"    </a>",
"    ]. A subset analysis comparing patients &ge;70 years found no difference in efficacy, although toxicity was significantly increased during the induction phase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another randomized trial from SWOG evaluated the use of the EGFR inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    after definitive chemoradiotherapy plus consolidation chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/112\">",
"     112",
"    </a>",
"    ]. A total of 571 patients with stage III NSCLC were treated with the same chemoradiotherapy schedule and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    consolidation as used in the HOG trial noted above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/96\">",
"     96",
"    </a>",
"    ]. After restaging, 243 patients without evidence of progression were randomly assigned to placebo or gefitinib [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/112\">",
"     112",
"    </a>",
"    ]. The median survival for those randomly assigned to gefitinib was significantly shorter than for those assigned to placebo (23 versus 35 months, HR 0.63, 95% CI 0.44-0.91). The poorer survival with maintenance gefitinib was due to tumor progression and could not be accounted for by gefitinib toxicity or imbalances in known prognostic factors within the study population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined modality therapy is the standard approach for the treatment of patients with unresected pathologic stage III NSCLC. Concurrent chemoradiotherapy with platinum-based chemotherapy provides a survival benefit compared to sequential chemotherapy followed by RT or to RT alone. Despite the increase in acute toxicity, this approach has emerged as the preferred regimen for patients who are candidates for aggressive treatment. Current evidence supports the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    at regular systemic doses or the weekly regimen of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    with external beam radiation.",
"   </p>",
"   <p>",
"    Induction (neoadjuvant) chemotherapy may be useful in patients with extensive disease that cannot be encompassed within a reasonably safe RT portal. This can be followed by concurrent chemoradiotherapy or definitive RT alone if an adequate response is obtained.",
"   </p>",
"   <p>",
"    The role of surgery in patients with pathologically documented mediastinal (N2) lymph node involvement remains a subject of debate. Patients being considered for surgery in this setting should always reviewed by a multidisciplinary team. Although, in randomized trials surgery after induction chemotherapy or chemoradiotherapy has not been shown to increase survival compared to definitive chemoradiotherapy alone, surgery may be appropriate for selected, otherwise healthy patients with a limited burden of disease in the mediastinum.",
"   </p>",
"   <p>",
"    For patients with a poor performance status, use of induction chemotherapy, single agent chemotherapy with radiation, or the weekly chemoradiotherapy approach are reasonable options.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H674548218\">",
"    <span class=\"h1\">",
"     BISPHOSPHONATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    has been shown to significantly reduce the incidence of skeletal related events in patients with bone metastases from NSCLC and other solid tumors,&nbsp;the administration of&nbsp;zoledronic acid every three to four weeks did not improve progression-free survival or overall survival in a phase III trial in patients treated for stage III NSCLC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102893541\">",
"    <span class=\"h1\">",
"     POOR PERFORMANCE STATUS PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;No standard approach exists for poor-risk patients who are not candidates for standard combined modality therapy. Thoracic radiotherapy, preferably with sensitizing chemotherapy, perhaps a single agent, is a reasonable strategy in the absence of more definitive data. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26199?source=see_link\">",
"     \"Systemic therapy for poor performance status patients with advanced non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     POSTTHERAPY SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few if any data are available to support evidence-based guidelines for posttreatment surveillance of patients with NSCLC. Nevertheless, recommendations from the American Society of Clinical Oncology are available, which were updated in January 2004 (",
"    <a class=\"graphic graphic_table graphicRef52008 \" href=\"mobipreview.htm?41/25/42395\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/36/39498/abstract/47\">",
"     47",
"    </a>",
"    ]. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/5/1114?source=see_link&amp;anchor=H29#H29\">",
"     \"Management of stage I and stage II non-small cell lung cancer\", section on 'Post therapy surveillance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/44/3779?source=see_link\">",
"       \"Patient information: Non-small cell lung cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/22/41314?source=see_link\">",
"       \"Patient information: Non-small cell lung cancer treatment; stage I to III cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/63/17396?source=see_link\">",
"       \"Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stage III NSCLC (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"mobipreview.htm?36/41/37533\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74820 \" href=\"mobipreview.htm?19/43/20157\">",
"     table 3",
"    </a>",
"    ) includes a highly heterogeneous group of patients due to differences in the extent and localization of disease (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Staging'",
"    </a>",
"    above). The optimal therapeutic approach is not well defined and depends upon multiple factors. We recommend that patients be enrolled in clinical trials whenever possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Unresected stage III disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;We do",
"    <strong>",
"     not",
"    </strong>",
"    recommend surgical resection as the initial treatment when pathologic involvement of mediastinal lymph nodes (N2 or N3) is documented prior to definitive treatment (",
"    <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"     Grade 1A",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend concurrent chemoradiotherapy with a platinum-based doublet for patients whose overall medical condition and performance status is acceptable (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"local\" href=\"#H32\">",
"       'Concurrent chemoradiotherapy'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Since both the &ldquo;full dose chemotherapy&rdquo; approach and the &ldquo;radiosensitizing chemotherapy&rdquo; approach have not been compared directly, either one of these are acceptable options for use in combination with radiotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The &ldquo;full dose regimen&rdquo; consists of two cycles of concurrent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1, 8, 29, and 36) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      (50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily on days 1 to 5 and 29 to 33) with once daily chest RT beginning on day 1 to approximately 60 Gy. The radiosensitizing regimen consists of weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      (AUC = 2) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      (45",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      followed by two cycles of standard dose of carboplatin (AUC = 6) and paclitaxel (200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ).",
"      </span>",
"     </li>",
"     <li>",
"      We recommend a radiation dose of approximately 60 Gy in 30 fractions in this setting, rather than a higher dose of RT (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Dose and local control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Elderly patients also appear to benefit from the addition of chemotherapy to radiotherapy for stage III NSCLC. This approach should be limited to elderly patients with a good performance status. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Elderly patients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend",
"      <strong>",
"       not",
"      </strong>",
"      using consolidation chemotherapy following completion of concurrent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      chemotherapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Standard-dose chemotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H36\">",
"       'Consolidation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are unable or unwilling to tolerate the toxicity associated with concurrent chemoradiotherapy, we recommend either sequential chemotherapy followed by definitive RT or definitive RT alone (approximately 60 Gy in 30 fractions) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      )&nbsp;(see",
"      <a class=\"local\" href=\"#H12\">",
"       'Definitive RT'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      If the tumor cannot be encompassed within a RT treatment portal with an acceptable risk of radiation pneumonitis, we recommend induction chemotherapy rather than concurrent chemoradiotherapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In such cases, concurrent chemoradiotherapy or definitive RT can be administered subsequently if an adequate response to chemotherapy is obtained (see",
"      <a class=\"local\" href=\"#H35\">",
"       'Induction chemotherapy followed by chemoradiotherapy'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Even though resection may be technically feasible in patients with limited mediastinal disease at presentation or following induction therapy, the role of surgery remains controversial. Surgery following induction chemotherapy or chemoradiotherapy may be appropriate for selected, otherwise healthy patients with a limited burden of disease, particularly if the tumor can be resected with lobectomy rather than pneumonectomy. The role of surgery in this setting is controversial when the patient requires a pneumonectomy&nbsp;(see",
"      <a class=\"local\" href=\"#H25\">",
"       'Preoperative induction therapy'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Resected stage IIIA disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H358237191\">",
"    <span class=\"h3\">",
"     Unsuspected N2 involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who have clinical stage I or II disease found to have unsuspected mediastinal lymph node involvement (N2) at resection or in the surgical resection specimen, we recommend adjuvant chemotherapy with a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based doublet if the patient's overall medical condition permits (",
"    <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"     Grade 1A",
"    </a>",
"    ) (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17833?source=see_link\">",
"     \"Adjuvant systemic therapy in resectable non-small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H6\">",
"     'Resected stage IIIA disease'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h3\">",
"     T3N1 disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with T3 chest wall or proximal airway tumors (within 2 cm of the carina) who have hilar (N1) lymph node involvement and a negative pathologic evaluation of the mediastinal (N2-3) lymph nodes are also classified as stage IIIA.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with surgically resectable T3N1 disease, we recommend surgery followed by adjuvant chemotherapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H7\">",
"       'T3N1 disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17833?source=see_link\">",
"       \"Adjuvant systemic therapy in resectable non-small cell lung cancer\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For T3N1 lesions that are not surgically resectable, we recommend concurrent chemoradiotherapy for patients whose overall medical condition and performance status is acceptable (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H32\">",
"       'Concurrent chemoradiotherapy'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H358237312\">",
"    <span class=\"h3\">",
"     Postoperative RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although survival is often limited by the development of distant metastatic disease, postoperative RT may prevent locoregional recurrence and may improve survival in patients with N2 lymph node involvement. (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Postoperative RT'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If surgical resection margins are positive or uncertain (&le;1 mm), we recommend postoperative RT as well as adjuvant chemotherapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The optimal sequencing of the adjuvant chemotherapy and RT is unknown. Sequential chemoradiotherapy will be associated with less toxicity than concurrent treatment.",
"     </li>",
"     <li>",
"      For patients with inadequate lymph node sampling in whom mediastinal node involvement was suspected but not confirmed, we suggest postoperative RT (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The use of PORT in this scenario should not be prioritized over that of adjuvant chemotherapy.",
"     </li>",
"     <li>",
"      For patients with involvement of multiple stations of involved N2 lymph nodes (following administration of adjuvant chemotherapy), we suggest adjuvant postoperative RT (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Advanced primary lesions (T4N0-1)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasional patients with advanced primary lesions (T4) present without evidence of mediastinal lymph node involvement or distant metastases (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Staging'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend surgery for the subset of patients with a separate nodule in a different lobe of the ipsilateral lung, if technically feasible (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Separate tumor nodules'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      In rare cases, the subset of patients with a T4 lesion and the absence of mediastinal nodal involvement by direct invasion may benefit from surgery if technically in the context of a multimodality approach. (See",
"      <a class=\"local\" href=\"#H522757065\">",
"       'T4N0-1 disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Separate solitary tumor nodules in both lungs may represent M1a disease or synchronous unrelated primary tumors. Detailed evaluation, including preoperative biopsies and mediastinoscopy, may be helpful in selecting patients for aggressive therapy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Separate tumor nodules'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest adjuvant chemotherapy if the primary lesion is successfully resected (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ) (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Adjuvant therapy in resected patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend postoperative RT if resection margins are positive or uncertain (&le;1 mm) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ) (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Postoperative RT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend concurrent chemoradiotherapy for patients with unresectable T4 primary lesions (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ) (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Concurrent chemoradiotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87285625\">",
"    <span class=\"h2\">",
"     Prophylactic cranial irradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with stage III NSCLC are at high risk for the subsequent development of brain metastases. PCI cannot be recommended at this time for stage III NSCLC outside the setting of a clinical trial. Although PCI decreases the incidence of brain metastases compared with observation, there is no improvement in disease-free or overall survival, and memory impairment can occur in some patients with PCI. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Prophylactic cranial irradiation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Malignant effusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with malignant pleural or pericardial effusions are classified as stage IV (M1a) in the revised staging system (",
"    <a class=\"graphic graphic_table graphicRef74820 \" href=\"mobipreview.htm?19/43/20157\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef68104 \" href=\"mobipreview.htm?13/4/13388\">",
"     table 2",
"    </a>",
"    ). These patients carry the same prognosis as those with stage IV disease. The management of malignant effusions and the treatment of advanced disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/6/13416?source=see_link\">",
"     \"Management of malignant pleural effusions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/1/1050?source=see_link\">",
"     \"Pericardial disease associated with malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link\">",
"     \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/1\">",
"      Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/2\">",
"      Robinson LA, Wagner H Jr, Ruckdeschel JC, American College of Chest Physicians. Treatment of stage IIIA non-small cell lung cancer. Chest 2003; 123:202S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/3\">",
"      Robinson LA, Ruckdeschel JC, Wagner H Jr, et al. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132:243S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/4\">",
"      Lee PC, Port JL, Korst RJ, et al. Risk factors for occult mediastinal metastases in clinical stage I non-small cell lung cancer. Ann Thorac Surg 2007; 84:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/5\">",
"      De Leyn P, Lardinois D, Van Schil P, et al. European trends in preoperative and intraoperative nodal staging: ESTS guidelines. J Thorac Oncol 2007; 2:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/6\">",
"      Meyers BF, Haddad F, Siegel BA, et al. Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer. J Thorac Cardiovasc Surg 2006; 131:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/7\">",
"      Graeter TP, Hellwig D, Hoffmann K, et al. Mediastinal lymph node staging in suspected lung cancer: comparison of positron emission tomography with F-18-fluorodeoxyglucose and mediastinoscopy. Ann Thorac Surg 2003; 75:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/8\">",
"      Pairolero PC, Trastek VF, Payne WS. Treatment of bronchogenic carcinoma with chest wall invasion. Surg Clin North Am 1987; 67:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/9\">",
"      Piehler JM, Pairolero PC, Weiland LH, et al. Bronchogenic carcinoma with chest wall invasion: factors affecting survival following en bloc resection. Ann Thorac Surg 1982; 34:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/10\">",
"      Harpole DH Jr, Healey EA, DeCamp MM Jr, et al. Chest wall invasive non-small cell lung cancer: patterns of failure and implications for a revised staging system. Ann Surg Oncol 1996; 3:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/11\">",
"      McCaughan BC, Martini N, Bains MS, McCormack PM. Chest wall invasion in carcinoma of the lung. Therapeutic and prognostic implications. J Thorac Cardiovasc Surg 1985; 89:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/12\">",
"      Port JL, Korst RJ, Lee PC, et al. Surgical resection for multifocal (T4) non-small cell lung cancer: is the T4 designation valid? Ann Thorac Surg 2007; 83:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/13\">",
"      Osaki T, Sugio K, Hanagiri T, et al. Survival and prognostic factors of surgically resected T4 non-small cell lung cancer. Ann Thorac Surg 2003; 75:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/14\">",
"      Nagai K, Sohara Y, Tsuchiya R, et al. Prognosis of resected non-small cell lung cancer patients with intrapulmonary metastases. J Thorac Oncol 2007; 2:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/15\">",
"      Ohta M, Hirabayasi H, Shiono H, et al. Surgical resection for lung cancer with infiltration of the thoracic aorta. J Thorac Cardiovasc Surg 2005; 129:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/16\">",
"      de Perrot M, Fadel E, Mussot S, et al. Resection of locally advanced (T4) non-small cell lung cancer with cardiopulmonary bypass. Ann Thorac Surg 2005; 79:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/17\">",
"      Mitchell JD, Mathisen DJ, Wright CD, et al. Resection for bronchogenic carcinoma involving the carina: long-term results and effect of nodal status on outcome. J Thorac Cardiovasc Surg 2001; 121:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/18\">",
"      Regnard JF, Perrotin C, Giovannetti R, et al. Resection for tumors with carinal involvement: technical aspects, results, and prognostic factors. Ann Thorac Surg 2005; 80:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/19\">",
"      Leo F, Bellini R, Conti B, et al. Superior vena cava resection in thoracic malignancies: does prosthetic replacement pose a higher risk? Eur J Cardiothorac Surg 2010; 37:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/20\">",
"      Spaggiari L, Leo F, Veronesi G, et al. Superior vena cava resection for lung and mediastinal malignancies: a single-center experience with 70 cases. Ann Thorac Surg 2007; 83:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/21\">",
"      Grunenwald DH, Mazel C, Girard P, et al. Radical en bloc resection for lung cancer invading the spine. J Thorac Cardiovasc Surg 2002; 123:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/22\">",
"      Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995; 13:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/23\">",
"      Govindan R, Bogart J, Wang X, et al. A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407- Early evaluation of feasibility and toxicity (abstract # 7518). J Clin Oncol 2008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/24\">",
"      Blumenschein GR Jr, Paulus R, Curran WJ, et al. Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol 2011; 29:2312.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health Clinical Trials database file://www.clinicaltrials.gov/ (Accessed on May 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/26\">",
"      Roswit B, Patno ME, Rapp R, et al. The survival of patients with inoperable lung cancer: a large-scale randomized study of radiation therapy versus placebo. Radiology 1968; 90:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/27\">",
"      Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/28\">",
"      Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995; 87:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/29\">",
"      Johnson DH, Einhorn LH, Bartolucci A, et al. Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann Intern Med 1990; 113:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/30\">",
"      Basaki K, Abe Y, Aoki M, et al. Prognostic factors for survival in stage III non-small-cell lung cancer treated with definitive radiation therapy: impact of tumor volume. Int J Radiat Oncol Biol Phys 2006; 64:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/31\">",
"      Perez CA, Bauer M, Edelstein S, et al. Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys 1986; 12:539.",
"     </a>",
"    </li>",
"    <li>",
"     Bradley JD, Paulus R, Komaki R, et al. Randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 GY) conformal chemoradiotherapy with or without cetuximab for stage IIIA/IIIB non-small cell lung cancer: Preliminary findings  on radiation dose in RTOG 0617 (abstract #LBA2). 53rd ASTRO Annual Meeting. October 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/33\">",
"      Mauguen A, Le P&eacute;choux C, Saunders MI, et al. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol 2012; 30:2788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/34\">",
"      Harpole DH Jr, Herndon JE 2nd, Young WG Jr, et al. Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. Cancer 1995; 76:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/35\">",
"      Kelsey CR, Clough RW, Marks LB. Local recurrence following initial resection of NSCLC: salvage is possible with radiation therapy. Cancer J 2006; 12:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/36\">",
"      Falk SJ, Girling DJ, White RJ, et al. Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial. BMJ 2002; 325:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/37\">",
"      Sawyer TE, Bonner JA, Gould PM, et al. Effectiveness of postoperative irradiation in stage IIIA non-small cell lung cancer according to regression tree analyses of recurrence risks. Ann Thorac Surg 1997; 64:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/38\">",
"      Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 1998; 352:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/39\">",
"      Bonner JA, Spencer SA. Postoperative radiotherapy in non-small-cell lung cancer warrants further exploration in the era of adjuvant chemotherapy and conformal radiotherapy. J Clin Oncol 2006; 24:2978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/40\">",
"      Dautzenberg B, Arriagada R, Chammard AB, et al. A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Groupe d'Etude et de Traitement des Cancers Bronchiques. Cancer 1999; 86:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/41\">",
"      Lally BE, Zelterman D, Colasanto JM, et al. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol 2006; 24:2998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/42\">",
"      Lally BE, Detterbeck FC, Geiger AM, et al. The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy: analysis of the Surveillance, Epidemiology, and End Results database. Cancer 2007; 110:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/43\">",
"      Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/44\">",
"      Douillard JY, Rosell R, De Lena M, et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys 2008; 72:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/45\">",
"      Le P&eacute;choux C, Dunant A, Pignon JP, et al. Need for a new trial to evaluate adjuvant postoperative radiotherapy in non-small-cell lung cancer patients with N2 mediastinal involvement. J Clin Oncol 2007; 25:e10.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/47\">",
"      Pisters KM, Evans WK, Azzoli CG, et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol 2007; 25:5506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/48\">",
"      Reddy S, Lee MS, Bonomi P, et al. Combined modality therapy for stage III non-small cell lung carcinoma: results of treatment and patterns of failure. Int J Radiat Oncol Biol Phys 1992; 24:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/49\">",
"      Gaspar LE, Chansky K, Albain KS, et al. Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group. J Clin Oncol 2005; 23:2955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/50\">",
"      Carolan H, Sun AY, Bezjak A, et al. Does the incidence and outcome of brain metastases in locally advanced non-small cell lung cancer justify prophylactic cranial irradiation or early detection? Lung Cancer 2005; 49:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/51\">",
"      Chen AM, Jahan TM, Jablons DM, et al. Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: clinical implications for the subsequent management of the brain. Cancer 2007; 109:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/52\">",
"      Cox JD, Stanley K, Petrovich Z, et al. Cranial irradiation in cancer of the lung of all cell types. JAMA 1981; 245:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/53\">",
"      Umsawasdi T, Valdivieso M, Chen TT, et al. Role of elective brain irradiation during combined chemoradiotherapy for limited disease non-small cell lung cancer. J Neurooncol 1984; 2:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/54\">",
"      Russell AH, Pajak TE, Selim HM, et al. Prophylactic cranial irradiation for lung cancer patients at high risk for development of cerebral metastasis: results of a prospective randomized trial conducted by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1991; 21:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/55\">",
"      Lester JF, MacBeth FR, Coles B. Prophylactic cranial irradiation for preventing brain metastases in patients undergoing radical treatment for non-small-cell lung cancer: a Cochrane Review. Int J Radiat Oncol Biol Phys 2005; 63:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/56\">",
"      P&ouml;ttgen C, Eberhardt W, Grannass A, et al. Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial. J Clin Oncol 2007; 25:4987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/57\">",
"      Gore EM, Bae K, Wong SJ, et al. Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol 2011; 29:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/58\">",
"      Sun A, Bae K, Gore EM, et al. Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol 2011; 29:279.",
"     </a>",
"    </li>",
"    <li>",
"     Gore EM, Paulus R, Wong S, et al. Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: Updated analysis of RTOG 0214 (abstract 5). J Thorac Oncol 2012; 7:S204.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/60\">",
"      Rosell R, G&oacute;mez-Codina J, Camps C, et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999; 26:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/61\">",
"      Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994; 86:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/62\">",
"      Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/63\">",
"      Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002; 20:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/64\">",
"      Shields TW. Preoperative radiation therapy in the treatment of bronchial carcinoma. Cancer 1972; 30:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/65\">",
"      Sherman DM, Neptune W, Weichselbaum R, et al. An aggressive approach to marginally resectable lung cancer. Cancer 1978; 41:2040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/66\">",
"      Warram J. Preoperative irradiation of cancer of the lung: final report of a therapeutic trial. A collaborative study. Cancer 1975; 36:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/67\">",
"      Choi NC, Carey RW, Daly W, et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J Clin Oncol 1997; 15:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/68\">",
"      Skarin A, Jochelson M, Sheldon T, et al. Neoadjuvant chemotherapy in marginally resectable stage III M0 non-small cell lung cancer: long-term follow-up in 41 patients. J Surg Oncol 1989; 40:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/69\">",
"      Elias AD, Skarin AT, Gonin R, et al. Neoadjuvant treatment of stage IIIA non-small cell lung cancer. Long-term results. Am J Clin Oncol 1994; 17:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/70\">",
"      Elias AD, Skarin AT, Leong T, et al. Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC). Lung Cancer 1997; 17:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/71\">",
"      Strauss GM, Herndon JE, Sherman DD, et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. J Clin Oncol 1992; 10:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/72\">",
"      Sugarbaker DJ, Herndon J, Kohman LJ, et al. Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group. J Thorac Cardiovasc Surg 1995; 109:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/73\">",
"      Martini N, Kris MG, Flehinger BJ, et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993; 55:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/74\">",
"      Burkes RL, Shepherd FA, Blackstein ME, et al. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3, N2) unresectable non-small-cell lung cancer: final results of the Toronto phase II trial. Lung Cancer 2005; 47:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/75\">",
"      Weitberg AB, Yashar J, Glicksman AS, et al. Combined modality therapy for stage IIIA non-small cell carcinoma of the lung. Eur J Cancer 1993; 29A:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/76\">",
"      Weiden PL, Piantadosi S. Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small-cell lung cancer: a phase II study of the Lung Cancer Study Group. J Natl Cancer Inst 1991; 83:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/77\">",
"      DeCamp MM, Rice TW, Adelstein DJ, et al. Value of accelerated multimodality therapy in stage IIIA and IIIB non-small cell lung cancer. J Thorac Cardiovasc Surg 2003; 126:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/78\">",
"      Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009; 374:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/79\">",
"      van Meerbeeck JP, Kramer GW, Van Schil PE, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007; 99:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/80\">",
"      Weder W, Collaud S, Eberhardt WE, et al. Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer. J Thorac Cardiovasc Surg 2010; 139:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/81\">",
"      Refai M, Brunelli A, Rocco G, et al. Does induction treatment increase the risk of morbidity and mortality after pneumonectomy? A multicentre case-matched analysis. Eur J Cardiothorac Surg 2010; 37:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/82\">",
"      Thomas M, R&uuml;be C, Hoffknecht P, et al. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer. Lancet Oncol 2008; 9:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/83\">",
"      Sauvaget J, Rebischung J, Vannetzel J. Phase III study of neoadjuvant MVP versus MVP plus chemoradiotherapy in stage III NSCLC. Proc Am Soc Clin Oncol 2000; 19:495a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/84\">",
"      Allen AM, Mentzer SJ, Yeap BY, et al. Pneumonectomy after chemoradiation: the Dana-Farber Cancer Institute/Brigham and Women's Hospital experience. Cancer 2008; 112:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/85\">",
"      Barnett SA, Rusch VW, Zheng J, et al. Contemporary results of surgical resection of non-small cell lung cancer after induction therapy: a review of 549 consecutive cases. J Thorac Oncol 2011; 6:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/86\">",
"      Sause W, Kolesar P, Taylor S IV, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000; 117:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/87\">",
"      Okawara G, Mackay JA, Evans WK, et al. Management of unresected stage III non-small cell lung cancer: a systematic review. J Thorac Oncol 2006; 1:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/88\">",
"      Chemotherapy for non-small cell lung cancer. Non-small Cell Lung Cancer Collaborative Group. Cochrane Database Syst Rev 2000; :CD002139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/89\">",
"      O'Rourke N, Roqu&eacute; I Figuls M, Farr&eacute; Bernad&oacute; N, Macbeth F. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2010; :CD002140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/90\">",
"      Curran WJ Jr, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 2011; 103:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/91\">",
"      Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17:2692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/92\">",
"      Furuse K, Hosoe S, Masuda N, et al. Impact of tumor control on survival in unresectable stage III non-small cell lung cancer (NSCLC) treated with concurrent thoracic radiotherapy and chemotherapy (abstract). Proc Am Soc Clin Oncol 2000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/93\">",
"      Arrieta O, Gallardo-Rinc&oacute;n D, Villarreal-Garza C, et al. High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin. J Thorac Oncol 2009; 4:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/94\">",
"      Albain KS, Crowley JJ, Turrisi AT 3rd, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 2002; 20:3454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/95\">",
"      Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003; 21:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/96\">",
"      Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008; 26:5755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/97\">",
"      Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005; 23:5883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/98\">",
"      Govindan R, Bogart J, Wang X, et al. A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407- Early evaluation of feasibility and toxicity (abstract #7518). J Clin Oncol 2008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/99\">",
"      Owonikoko TK, Ragin CC, Belani CP, et al. Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 2007; 25:5570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/100\">",
"      Sequist LV, Lynch TJ. Aggressive treatment for the fit elderly with non-small-cell lung cancer? Yes! J Clin Oncol 2003; 21:3186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/101\">",
"      Schild SE, Stella PJ, Geyer SM, et al. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 2003; 21:3201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/102\">",
"      Rocha Lima CM, Herndon JE 2nd, Kosty M, et al. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. Cancer 2002; 94:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/103\">",
"      Langer CJ, Hus C, Curran WJ, et al. Elderly patients (pts) with locally advanced non-small cell lung cancer (LA-NSCLC) benefit from combined modality therapy: secondary analysis of Radiation Therapy Oncology Group (abstrac #1193). Proc Am Soc Clin Oncol 2002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/104\">",
"      Atagi S, Kawahara M, Yokoyama A, et al. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol 2012; 13:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/105\">",
"      Schild SE, Mandrekar SJ, Jatoi A, et al. The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer. Cancer 2007; 110:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/106\">",
"      Hardy D, Liu CC, Cormier JN, et al. Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer. Ann Oncol 2010; 21:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/107\">",
"      Vokes EE, Herndon JE 2nd, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007; 25:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/108\">",
"      Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Fran&ccedil;ais de Pneumo-Canc&eacute;rologie NPC 95-01 Study. J Clin Oncol 2005; 23:5910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/109\">",
"      Lau DH, Crowley JJ, Gandara DR, et al. Southwest Oncology Group phase II trial of concurrent carboplatin, etoposide, and radiation for poor-risk stage III non-small-cell lung cancer. J Clin Oncol 1998; 16:3078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/110\">",
"      Davies AM, Chansky K, Lau DH, et al. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712. J Clin Oncol 2006; 24:5242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/111\">",
"      Jalal SI, Riggs HD, Melnyk A, et al. Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology. Ann Oncol 2012; 23:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/112\">",
"      Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008; 26:2450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/36/39498/abstract/113\">",
"      Scagliotti GV, Kosmidis P, de Marinis F, et al. Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study. Ann Oncol 2012; 23:2082.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4623 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C80C007BE0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_36_39498=[""].join("\n");
var outline_f38_36_39498=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H40\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H109591591\">",
"      TNM staging system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H109591606\">",
"      Mediastinal evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENERAL APPROACH TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Limitations of clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Resected stage IIIA disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      T3N1 disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Separate tumor nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H522757065\">",
"      T4N0-1 disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TARGETED THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RADIATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Definitive RT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Dose and local control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Altered fractionation schedules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Isolated thoracic recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Palliative RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ADJUVANT THERAPY IN RESECTED PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Postoperative RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Adjuvant chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Adjuvant chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Prophylactic cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      MANAGEMENT OF POTENTIALLY RESECTABLE STAGE III DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PREOPERATIVE INDUCTION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Induction chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Preoperative radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Preoperative chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      MANAGEMENT OF SURGICALLY UNRESECTABLE STAGE III DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      DEFINITIVE CHEMOTHERAPY AND RADIATION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Sequential chemotherapy and radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Concurrent chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Standard-dose chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Elderly patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Induction chemotherapy followed by chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Consolidation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H674548218\">",
"      BISPHOSPHONATES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102893541\">",
"      POOR PERFORMANCE STATUS PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      POSTTHERAPY SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Unresected stage III disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Resected stage IIIA disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H358237191\">",
"      - Unsuspected N2 involvement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      - T3N1 disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H358237312\">",
"      - Postoperative RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Advanced primary lesions (T4N0-1)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87285625\">",
"      Prophylactic cranial irradiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Malignant effusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/4623\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4623|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/41/37533\" title=\"table 1\">",
"      Lung cancer TMN staging 7th edition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/4/13388\" title=\"table 2\">",
"      Changes 7th ed TNM lung ca",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/43/20157\" title=\"table 3\">",
"      Lung cancer TMN staging 6th edition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/37/23133\" title=\"table 4\">",
"      Induction chemo stage III NSCLC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/25/42395\" title=\"table 5\">",
"      ASCO recommend lung CA followup",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/26/17833?source=related_link\">",
"      Adjuvant systemic therapy in resectable non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/21/34137?source=related_link\">",
"      Cardiotoxicity of radiation therapy for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/31/14841?source=related_link\">",
"      Diagnosis and staging of non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/42/20137?source=related_link\">",
"      Gastrointestinal toxicity of radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=related_link\">",
"      Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29946?source=related_link\">",
"      Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/6/13416?source=related_link\">",
"      Management of malignant pleural effusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/5/1114?source=related_link\">",
"      Management of stage I and stage II non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/58/14250?source=related_link\">",
"      Pancoast's syndrome and superior (pulmonary) sulcus tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/43/22201?source=related_link\">",
"      Pathology of lung malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/44/3779?source=related_link\">",
"      Patient information: Non-small cell lung cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/22/41314?source=related_link\">",
"      Patient information: Non-small cell lung cancer treatment; stage I to III cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/63/17396?source=related_link\">",
"      Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/1/1050?source=related_link\">",
"      Pericardial disease associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/50/1830?source=related_link\">",
"      Prophylactic cranial irradiation for patients with small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/36/40520?source=related_link\">",
"      Second-line therapy for patients with previously treated advanced non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/42/10922?source=related_link\">",
"      Systemic chemotherapy for cancer in elderly persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26199?source=related_link\">",
"      Systemic therapy for poor performance status patients with advanced non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/21/44373?source=related_link\">",
"      Tumor node metastasis (TNM) staging system for non-small cell lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_36_39499="Hematologic causes of NHF";
var content_f38_36_39499=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hematologic causes of nonimmune fetal hydrops",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Hemoglobinopathy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Alpha-thalassemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Hemorrhage",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fetomaternal hemorrhage",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       In utero fetal hemorrhage",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Defective red cell production",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Parvovirus B19",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Red cell enzyme deficiency",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pyruvate kinase deficiency",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Glucose phosphate isomerase deficiency",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Glucose-6-phosphate dehydrogenase deficiency",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Red cell structural abnormality",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Spectrin protein abnormality or deficiency",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Myeloproliferative disorders",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Transient myeloproliferative disorder",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Leukemoid reaction in response to congenital infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Congenital Leukemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Kasabach-Merritt syndrome (microangiopathic hemolytic anemia, DIC)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Other",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Blackfan Diamond anemia",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Arcasoy, M, Gallagher, P. Hematologic Disorders and Nonimmune Hydrops Fetalis. Semin Perinatol 1995; 19:502.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_36_39499=[""].join("\n");
var outline_f38_36_39499=null;
var title_f38_36_39500="Valproate interactions with other AEDs";
var content_f38_36_39500=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F53463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F53463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Some interactions between valproate and other antiepileptic drugs*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Interacting drugs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effects (probable mechanism)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Valproate, with:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Carbamazepine",
"       </td>",
"       <td>",
"        Decreased valproate effect and possible increased toxicity (increased metabolism and formation of toxic metabolite)",
"       </td>",
"       <td>",
"        Monitor valproate concentrations and clinical status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carbamazepine toxicity (decreased metabolism of carbamazepine epoxide and displacement from binding)",
"       </td>",
"       <td>",
"        Monitor carbamazepine and carbamazepine epoxide concentrations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clonazepam",
"       </td>",
"       <td>",
"        Clonazepam may precipitate absence status (mechanism not established)",
"       </td>",
"       <td>",
"        Monitor clinical status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Ethosuximide",
"       </td>",
"       <td>",
"        Possible ethosuximide toxicity (decreased metabolism)",
"       </td>",
"       <td>",
"        Monitor ethosuximide concentration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Possible decreased valproate effect (mechanism not established)",
"       </td>",
"       <td>",
"        Monitor valproate concentration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lamotrigine",
"       </td>",
"       <td>",
"        Possible lamotrigine toxicity (decreased metabolism; glucuronidation)",
"       </td>",
"       <td>",
"        Decrease lamotrigine dose; monitor lamotrigine concentrations and clinical status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Oxcarbazepine",
"       </td>",
"       <td>",
"        Possible decreased oxcabazepine concentration (increased metabolism)",
"       </td>",
"       <td>",
"        Monitor oxcarbazepine concentrations and clinical status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Phenytoin",
"       </td>",
"       <td>",
"        Phenytoin toxicity (displacement from binding and decreased metabolism)",
"       </td>",
"       <td>",
"        Monitor phenytoin concentrations and clinical status (unbound concentrations may be more helpful than total)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Possible decreased valproate effect and increased toxicity (increased metabolism and formation of toxic metabolite)",
"       </td>",
"       <td>",
"        Monitor clinical status and valproate serum concentrations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Topiramate",
"       </td>",
"       <td>",
"        Possible increased hepatotoxic effect of valproate (mechanism not established)",
"       </td>",
"       <td>",
"        Monitor clinical status",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *",
"     <strong>",
"      NOTE: Not all potential interactions are listed.",
"     </strong>",
"     Additional interactions of antiepileptic drugs and management suggestions may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. The Lexi-Interact program can be accessed from the UpToDate new search tab or through the individual drug information topics in the section on Drug interactions.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Drugs for Epilepsy. Treatment guidelines from The Medical Letter 2008; 6(70):37-46. Copyright &copy; 2008 The Medical Letter.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_36_39500=[""].join("\n");
var outline_f38_36_39500=null;
var title_f38_36_39501="Interdependence sens spec";
var content_f38_36_39501=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72237&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72237&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Depiction of interdependence of sensitivity and specificity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 287px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The curves represent serum aminotransferase levels for populations with and without chronic hepatitis. As the cutoff used for defining an abnormal value (blue line) is moved toward the right, more patients with hepatitis will be missed (loss of sensitivity). As the blue line is moved to the left, more patients without hepatitis will be incorrectly labeled as having hepatitis (loss of specificity).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_36_39501=[""].join("\n");
var outline_f38_36_39501=null;
var title_f38_36_39502="Active TB risk factors";
var content_f38_36_39502=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F60941&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F60941&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors for the development of active tuberculosis among persons infected with",
"    <em>",
"     Mycobacterium tuberculosis",
"    </em>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Risk factor",
"      </td>",
"      <td class=\"subtitle1\">",
"       Estimated risk for TB relative to persons with no known risk factor",
"      </td>",
"      <td class=\"subtitle1\">",
"       References",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       High risk",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Acquired immunodeficiency syndrome (AIDS)",
"      </td>",
"      <td>",
"       110-170",
"      </td>",
"      <td>",
"       1,2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Human immunodeficiency virus infection (HIV)",
"      </td>",
"      <td>",
"       50-110",
"      </td>",
"      <td>",
"       3,4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Transplantation (related to immune-suppressant therapy)",
"      </td>",
"      <td>",
"       20-74",
"      </td>",
"      <td>",
"       5-8",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Silicosis",
"      </td>",
"      <td>",
"       30",
"      </td>",
"      <td>",
"       9,10",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Chronic renal failure requiring hemodialysis",
"      </td>",
"      <td>",
"       10-25",
"      </td>",
"      <td>",
"       11-14",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Carcinoma of head and neck",
"      </td>",
"      <td>",
"       16.0",
"      </td>",
"      <td>",
"       15",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Recent TB infection (&le;2 years)",
"      </td>",
"      <td>",
"       15.0",
"      </td>",
"      <td>",
"       16,17",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Abnormal chest x-ray with apical fibronodular changes typical of healed TB (not granuloma)",
"      </td>",
"      <td>",
"       6-19",
"      </td>",
"      <td>",
"       18-20",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Tumor necrosis factor (TNF)-alpha inhibitors",
"      </td>",
"      <td>",
"       1.7-9",
"      </td>",
"      <td>",
"       21,22,35,36",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Moderate risk",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Treatment with glucocorticoids",
"      </td>",
"      <td>",
"       4.9",
"      </td>",
"      <td>",
"       23",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Diabetes mellitus (all types)",
"      </td>",
"      <td>",
"       2-3.6",
"      </td>",
"      <td>",
"       24-27",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Young age when infected (&le;4 years)",
"      </td>",
"      <td>",
"       2.2-5",
"      </td>",
"      <td>",
"       28",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Slightly increased risk",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Underweight (&lt;85 percent of ideal body weight); for most individuals this is equivalent to body mass index (BMI) &le;20.",
"      </td>",
"      <td>",
"       2-3",
"      </td>",
"      <td>",
"       29",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Cigarette smoker (1 pack/day)",
"      </td>",
"      <td>",
"       2-3",
"      </td>",
"      <td>",
"       30,31",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Chest x-ray with solitary granuloma",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       20,32",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Low risk",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Infected person, no known risk factor, normal chest x-ray (\"low risk reactor\")",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       33",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Very low risk",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Positive booster (two step test) with no other known risk factor and normal chest x-ray)",
"      </td>",
"      <td>",
"       0.5",
"      </td>",
"      <td>",
"       Extrapolated from 33 and 34",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     1.&nbsp; Guelar, A., J. M. Gatell, J. Verdejo, D. Podzamczer, L. Lozano, E. Aznar, J. M. Miro, J. Mallolas, L. Zamora, J. Gonzales, and E. Soriano. 1993. A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS 7:1345-1349.",
"     <br>",
"      2.&nbsp; Antonucci, G., E. Girardi, M. C. Raviglione, G. Ippolito, and for the GISTA. 1995. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. JAMA 274:143-148.",
"      <br>",
"       3.&nbsp; Wood R, Maartens G, and Lombard CJ. 2000. Risk factors for developing tuberculosis in HIV-1 - Infected adults from communities with low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr 23:75-80.",
"       <br>",
"        4.&nbsp; Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, Walker AT, and Friedland GH. 1989. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. New Engl J Med 320:545-550.",
"        <br>",
"         5.&nbsp; Sakhuja, V., V. Jha, P. P. Varma, K. Joshi, and K. S. Chugh. 1996. The high incidence of tuberculosis among renal transplant recipients in India. Transplantation 61:211-215.",
"         <br>",
"          6.&nbsp; Aguado, J. M., J. A. Herrero, J. Gavalda, J. Torre-Cisneros, M. Blanes, G. Rufi, A. Moreno, M. Gurgui, M. Hayek, C. Lumbreras, and C. Cantarell. 1997. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Transplantation 63:1278-1286.",
"          <br>",
"           7.&nbsp; Miller, R. A., L. A. Lanza, J. N. Kline, and L. J. Geist. 1995. Mycobacterium tuberculosis in lung transplant recipients. Am J Respir Crit Care Med 152:374-376.",
"           <br>",
"            8.&nbsp; Meyers, B. R., M. Halpern, P. Sheiner, M. H. Mendelson, E. Neibart, and C. Miller. 1994. Tuberculosis in liver transplant patients. Transplantation 58:301-306.",
"            <br>",
"             9.&nbsp; Hong Kong Chest Service Tuberculosis Research Centre, M. B. M. R. C. 1992. A Double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 145:36-41.",
"             <br>",
"              10. Cowie, R. L. 1994. The epidemiology of tuberculosis in gold miners with silicosis. Am J Respir Crit Care Med 150:1460-1462.",
"              <br>",
"               11. Malhotra, K. K., M. K. Parashar, R. K. Sharma, U. N. Bhuyan, S. C. Dash, R. Kumar, and D. S. Rana. 1981. Tuberculosis in maintenance haemodialysis patients. Study from an endemic area. Postgrad.Med J 57:492-498.",
"               <br>",
"                12. Lundin, A. P., A. J. Adler, G. M. Berlyne, and E. A. Friedman. 1979. Tuberculosis in patients undergoing maintenance hemodialysis. Am J Med 67:597-602.",
"                <br>",
"                 13. Andrew, O. T., P. Y. Schoenfeld, P. C. Hopewell, and M. H. Humphreys. 1980. Tuberculosis in patients with end-stage renal disease. Am J Med 68:59-65.",
"                 <br>",
"                  14. Pradhan, R. P., L. A. Katz, B. D. Nidus, R. Matalon, and R. P. Eisinger. 1974. Tuberculosis in dialyzed patients. JAMA 229:798-800.",
"                  <br>",
"                   15. Rieder, H. L., G. M. Cauthen, G. W. Comstock, and D. E. Snider, Jr. 1989. Epidemiology of tuberculosis in the United States. Epidemiol.Rev. 11:79-98.",
"                   <br>",
"                    16. Sutherland I. 1976. Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli. Adv Tuberc Res 19:1-63.",
"                    <br>",
"                     17. Sutherland, I. 1966. The evolution of clinical tuberculosis in adolescents. Tuberc 47:308.",
"                     <br>",
"                      18. Nolan CM and Elarth AM. 1988. Tuberculosis in a cohort of Southeast Asian refugees: A five-year surveillance study. Am Rev Resp Dis 137:805-809.",
"                      <br>",
"                       19. Grzybowksi, S., N. E. McKinnon, L. Tuters, G. Pinkus, and R. Philipps. 1966. Reactivations in inactive pulmonary tuberculosis. Am Rev Resp Dis 93:352-360.",
"                       <br>",
"                        20. Grzybowski, S., H. Fishaut, J. Rowe, and A. Brown. 1971. Tuberculosis among patients with various radiologic abnormalities, followed by the chest clinic service. Am Rev Resp Dis 104:605-608.",
"                        <br>",
"                         21. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, and Braun MM. 2001. Tuberculosis associated with infliximab, a tumor necrosis factor ? - neutralizing agent. The New England Journal of Medicine 345:1098-1104.",
"                         <br>",
"                          22. Brassard, P., A. Kezouh, and S. Suissa. 2006. Antirheumatic drugs and the risk of tuberculosis. Clin.Infect.Dis 43:717-722.",
"                          <br>",
"                           23. Jick, S. S., E. S. Lieberman, M. U. Rahman, and H. K. Choi. 2006. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum. 55:19-26.",
"                           <br>",
"                            24. Kim, S. J., Y. P. Hong, W. J. Lew, S. C. Yang, and E. G. Lee. 1995. Incidence of pulmonary tuberculosis among diabetics. Tuber.Lung Dis. 76:529-533.",
"                            <br>",
"                             25. Silwer H. and Oscarsson P.N. 1958. Incidence and coincidence of diabetes mellitus and pulmonary tuberculosis in a Swedish county. Acta Med Scand. 161:1-48.",
"                             <br>",
"                              26. Pablos-Mendez, A., J. Blustein, and C. A. Knirsch. 1997. The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. Am J Public Health 87:574-579.",
"                              <br>",
"                               27. Boucot KR. 1957. Diabetes mellitus and pulmonary tuberculosis. J Chronic.Dis 6:256-279.",
"                               <br>",
"                                28. Comstock, G. W., V. T. Livesay, and S. F. Woolpert. 1974. The prognosis of a positive tuberculin reaction in childhood and adolescence. American Journal of Epidemiology. 99:131-137.",
"                                <br>",
"                                 29. Comstock GW. 1975. Frost Revisited: The modern epidemiology of tuberculosis. Am J Epidemiology 101:263-382.",
"                                 <br>",
"                                  30. Maurya, V., V. K. Vijayan, and A. Shah. 2002. Smoking and tuberculosis: an association overlooked. Int.J Tuberc.Lung Dis. 6:942-951.",
"                                  <br>",
"                                   31. Gajalakshmi V, Peto R, Kanaka T, and Jha P. Smoking and mortality from tuberculosis and other diseases in India: retrospective study of 43000 adult male deaths and 35000 controls. The Lancet 362, 507. 2003.",
"                                   <br>",
"                                    Ref Type: Journal (Full)",
"                                    <br>",
"                                     32. Horwitz, O., E. Wilbek, and P. A. Erickson. 1969. Epidemiological basis of tubeculosis eradication. Longitudinal studies on the risk of tuberculosis in the general population of a low-prevalence area. Bull.Wld Hlth Org. 41:95-113.",
"                                     <br>",
"                                      33. Comstock GW, Edwards LB, and Livesay VT. 1974. Tuberculosis morbidity in the US Navy: its distribution and decline. Am Rev Respir Dis 110:572-580.",
"                                      <br>",
"                                       34. Ferebee SH. 1969. Controlled chemoprophylaxis trials in tuberculosis. Adv Tuberc Res 17:28-106.",
"                                       <br>",
"                                        35. Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 2004 Feb;50(2):372-9.",
"                                        <br>",
"                                         36. Carmona L, G&oacute;mez-Reino JJ, Rodr&iacute;guez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 2005 Jun;52(6):1766-72.",
"                                        </br>",
"                                       </br>",
"                                      </br>",
"                                     </br>",
"                                    </br>",
"                                   </br>",
"                                  </br>",
"                                 </br>",
"                                </br>",
"                               </br>",
"                              </br>",
"                             </br>",
"                            </br>",
"                           </br>",
"                          </br>",
"                         </br>",
"                        </br>",
"                       </br>",
"                      </br>",
"                     </br>",
"                    </br>",
"                   </br>",
"                  </br>",
"                 </br>",
"                </br>",
"               </br>",
"              </br>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_36_39502=[""].join("\n");
var outline_f38_36_39502=null;
var title_f38_36_39503="Pituitary location PI";
var content_f38_36_39503=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F72262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F72262&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Pituitary gland",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 346px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The pituitary gland is a small organ at the base of the brain. It makes substances called \"hormones\" that control the way certain organs in the body work.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_36_39503=[""].join("\n");
var outline_f38_36_39503=null;
